GLP-1 Market
LLY $1169.60 ▼ -1.6% NVO $38.18 ▼ -0.2% PFE $27.82 ▼ -0.6% VKTX $27.73 ▼ -2.8% KLRA $10.00 ▼ -5.0% GPCR $25.67 ▼ -3.8% RHHBY $53.29 ▼ -1.4%
Market data delayed up to 20 min · Source: Twelve Data

Empowering you to have better conversations with your doctor.

Subscribe
About this data Sourced primarily from ClinicalTrials.gov — a listing isn't proof of safety or FDA approval.

Pipeline and clinical trial information here comes primarily from ClinicalTrials.gov. A listing on ClinicalTrials.gov means a study has been registered — not that a treatment is proven safe, effective, or FDA-approved. Investigational treatments may never be approved. Who can join a trial is decided only by that trial's own study team.

Not yet reported

Bendamustine Hydrochloride

Company
Columbia University
Mechanism
Mechanism not yet reported
Route
Route not yet reported
Recruiting trials
52 recruiting

Efficacy results: Not yet reported

Find a Clinical Trial Near Me

52 recruiting studies currently listed on ClinicalTrials.gov.

Data source: ClinicalTrials.gov · trial data as of Oct 9, 2026

Find a Clinical Trial Near Me

See recruiting studies for Bendamustine Hydrochloride and check eligibility with the study team.

Select conditions
Match
Treatment type

"Added to GLP-1" means the investigational treatment is being studied on top of an existing GLP-1-based therapy.

Your ZIP code is only used to calculate distance to trial sites — it isn't stored.

Trial details
  • Recruiting NCT NCT03980002

    A Prospective Multicenter Phase 2 Study of FCR/BR Alternating With Ibrutinib in Treatment-naive Patients With CLL

    Not yet reported Institute of Hematology & Blood Diseases Hospital, China 50 participants Est. completion 2027-12-30 1 site Stand-alone
    Other conditions: Chronic Lymphocytic Leukemia
    View official trial listing →
  • Recruiting NCT NCT04022239

    Bendamustine With or Without Cyclophosphamide in Preventing GVHD in Patients Undergoing Stem Cell Transplant

    Not yet reported, Not yet reported M.D. Anderson Cancer Center 25 participants Est. completion 2027-07-31 1 site Stand-alone
    Other conditions: Hematopoietic and Lymphoid System Neoplasm
    View official trial listing →
  • Recruiting NCT NCT04083495

    CD30 CAR for Relapsed/Refractory CD30+ T Cell Lymphoma

    Not yet reported UNC Lineberger Comprehensive Cancer Center 20 participants Est. completion 2038-08 2 sites Stand-alone
    Other conditions: Peripheral T Cell Lymphoma
    View official trial listing →
  • Recruiting NCT NCT04223765

    Study of Kappa Chimeric Antigen Receptor (CAR) T Lymphocytes Co-Expressing the Kappa and CD28 CARs for Relapsed/Refractory Kappa+ Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma.

    Not yet reported UNC Lineberger Comprehensive Cancer Center 20 participants Est. completion 2043-03-22 1 site Stand-alone
    Obstructive sleep apnea Other conditions: Mantle Cell Lymphoma, Follicular Lymphoma, Splenic Marginal Zone Lymphoma, Nodal Marginal Zone Lymphoma, Indolent Non-hodgkin Lymphoma
    View official trial listing →
  • Recruiting NCT NCT04510636

    Study of Pembrolizumab With Bendamustine in Hodgkin Lymphoma

    Not yet reported University Health Network, Toronto 40 participants Est. completion 2026-11-01 1 site Stand-alone
    Other conditions: Classical Hodgkin Lymphoma, Relapsed Cancer, Refractory Cancer
    View official trial listing →
  • Recruiting NCT NCT04587687

    Brentuximab Vedotin and Bendamustine for the Treatment of Relapsed or Refractory Follicular Lymphoma

    Not yet reported University of California, Davis 23 participants Est. completion 2028-05 1 site Stand-alone
    Other conditions: Recurrent Follicular Lymphoma, Refractory Follicular Lymphoma
    View official trial listing →
  • Recruiting NCT NCT04792489

    DALY II USA/ MB-CART2019.1 for DLBCL

    Not yet reported Miltenyi Biomedicine GmbH 315 participants Est. completion 2028-12-31 32 sites Stand-alone
    Other conditions: Refractory Diffuse Large B Cell Lymphoma (DLBCL), Relapsed Diffuse Large B Cell Lymphoma, High Grade B-cell Lymphoma (HGBCL), Primary Mediastinal B-cell Lymphoma (PMBCL), Transformed Lymphoma, Central Nervous System Lymphoma, Mantle Cell Lymphoma (MCL), Richter Transformation, Transplant-ineligible 2nd Line DLBCL
    View official trial listing →
  • Recruiting NCT NCT04844866

    Efficacy and Safety of MB-CART2019.1 vs. SoC in Lymphoma Patients

    Not yet reported Miltenyi Biomedicine GmbH 213 participants Est. completion 2031-09-30 51 sites
    Other conditions: Diffuse Large B-cell Lymphoma
    View official trial listing →
  • Recruiting NCT NCT04892277

    CD19-Directed CAR-T Cell Therapy for the Treatment of Relapsed/Refractory B Cell Malignancies

    Not yet reported Mayo Clinic 25 participants Est. completion 2040-03-27 1 site Stand-alone
    Other conditions: Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Chronic Lymphocytic Leukemia, Recurrent Small Lymphocytic Lymphoma, Recurrent Transformed Chronic Lymphocytic Leukemia, Refractory B-Cell Non-Hodgkin Lymphoma, Refractory Chronic Lymphocytic Leukemia, Refractory Small Lymphocytic Lymphoma, Refractory Transformed Chronic Lymphocytic Leukemia
    View official trial listing →
  • Recruiting NCT NCT05139017

    A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) (MK-2140-003)

    Not yet reported, Not yet reported Merck Sharp & Dohme LLC 290 participants Est. completion 2027-09-24 135 sites Stand-alone
    Other conditions: DLBCL, Diffuse Large B-Cell Lymphoma
    View official trial listing →
  • Recruiting NCT NCT05245656

    A Study Comparing Rituximab/Bendamustin(RB) Alternating With Rituximab/Bendamustin/Cytarabin(RBAC) With RB Therapy in Elderly Patients With Mentle Cell Lymphoma

    Not yet reported Kim, Seok Jin 90 participants Est. completion 2029-12-31 1 site Stand-alone
    Other conditions: Mantle Cell Lymphoma
    View official trial listing →
  • Recruiting NCT NCT05506410

    A Clinical Study of Hanlikang and BTK Inhibitors in the Treatment of Newly Diagnosed Mantle Cell Lymphoma

    Zhengzhou University 100 participants Est. completion 2026-12-30 1 site
    Other conditions: Newly Diagnosed Mantle Cell Lymphoma
    View official trial listing →
  • Recruiting NCT NCT05816850

    Multilayer Biological Characterization of Advanced Follicular Lymphoma: a Translational Study From FIL_FOLL12 Trial

    Fondazione Italiana Linfomi - ETS 654 participants Est. completion 2027-06-01 26 sites
    Other conditions: Follicular Lymphoma
    View official trial listing →
  • Recruiting NCT NCT05848765

    Relapsed Follicular Lymphoma Randomised Trial Against Standard ChemoTherapy

    Not yet reported University of Birmingham 284 participants Est. completion 2031-11-30 25 sites
    Other conditions: Relapsed Follicular Lymphoma, Refractory Follicular Lymphoma
    View official trial listing →
  • Recruiting NCT NCT05868395

    Efficacy of Polatuzumab, Bendamustine and Rituximab in Patients With Relapsed/ Refractory Mantle Cell Lymphoma

    Not yet reported Medical University of Vienna 16 participants Est. completion 2027-05-24 1 site Stand-alone
    Other conditions: Mantle-cell Lymphoma
    View official trial listing →
  • Recruiting NCT NCT05899621

    A Real-world Study of Obinutuzumab-based Therapy for Previously Untreated FL

    Ruijin Hospital 332 participants Est. completion 2027-06-30 1 site
    Other conditions: Follicular Lymphoma
    View official trial listing →
  • Recruiting NCT NCT06006117

    Mosunetuzumab-Lenalidomide Versus Investigator Choices in Patients With Relapsed or Refractory Marginal Zone Lymphoma

    Not yet reported The Lymphoma Academic Research Organisation 260 participants Est. completion 2032-09 48 sites
    Other conditions: Marginal Zone Lymphoma
    View official trial listing →
  • Recruiting NCT NCT06043713

    Autologous CD8+ and CD4+ Transgenic T Cells Expressing High Affinity KRASG12V Mutation-Specific T Cell Receptors (FH-A11KRASG12V-TCR) in Treating Patients With Metastatic Solid Tumor Cancers With KRAS G12V Mutations

    Not yet reported Fred Hutchinson Cancer Center 24 participants Est. completion 2028-01-01 1 site Stand-alone
    Other conditions: Metastatic Malignant Solid Neoplasm
    View official trial listing →
  • Recruiting NCT NCT06084936

    A Study to Evaluate Glofitamab as a Single Agent vs. Investigator's Choice in Participants With Relapsed/Refractory Mantle Cell Lymphoma

    Not yet reported Hoffmann-La Roche 182 participants Est. completion 2028-03-31 83 sites
    Other conditions: Lymphoma
    View official trial listing →
  • Recruiting NCT NCT06090864

    ATLCAR.CD30.CCR4 for CD30+ HL ATLCAR.CD30.CCR4 Cells

    Not yet reported, Not yet reported UNC Lineberger Comprehensive Cancer Center 31 participants Est. completion 2033-07-01 1 site Stand-alone
    Other conditions: Hodgkin Lymphoma, Relapse, Refractory
    View official trial listing →
  • Recruiting NCT NCT06091254

    A Trial to Learn if Odronextamab is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Different Types of Chemotherapy for Adult Participants With Previously Untreated Follicular Lymphoma

    Not yet reported Regeneron Pharmaceuticals 822 participants Est. completion 2029-11-03 190 sites
    Other conditions: Follicular Lymphoma (FL)
    View official trial listing →
  • Recruiting NCT NCT06136351

    A Study of the Zanubrutinib Given in Combination With Bendamustine and Rituximab in (Elderly or TP53 Alterations or Chemotherapy Intolerance) Patients With Newly Diagnosed Mantle Cell Lymphoma

    Not yet reported Ruijin Hospital 23 participants Est. completion 2027-11-01 1 site
    Other conditions: Lymphoma, Mantle-Cell
    View official trial listing →
  • Recruiting NCT NCT06138132

    A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell ( CAR-T) Therapy in Subjects With Non-relapsing and Progressive Forms of Multiple Sclerosis

    Not yet reported Stanford University 12 participants Est. completion 2027-06 1 site
    Other conditions: Multiple Sclerosis, Multiple Sclerosis, Primary Progressive, Multiple Sclerosis, Secondary Progressive
    View official trial listing →
  • Recruiting NCT NCT06170489

    A Phase III Clinical Study Comparing JS004 Plus Toripalimab With Investigator-Selected Chemotherapy in Patients With PD-(L)1monoclonal Antibody Refractory Classic Hodgkin Lymphoma (cHL)

    Not yet reported Shanghai Junshi Bioscience Co., Ltd. 185 participants Est. completion 2027-09-30 1 site
    Other conditions: Hodgkin Lymphoma
    View official trial listing →
  • Recruiting NCT NCT06191887

    B-Cell Activating Factor Receptor (BAFFR)-Based Chimeric Antigen Receptor T-Cells With Fludarabine and Cyclophosphamide Lymphodepletion for the Treatment of Relapsed or Refractory B-cell Hematologic Malignancies

    Not yet reported Mayo Clinic 27 participants Est. completion 2040-12-31 1 site Stand-alone
    Other conditions: B-Cell Non-Hodgkin Lymphoma, Recurrent Chronic Lymphocytic Leukemia, Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Follicular Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Marginal Zone Lymphoma, Recurrent Small Lymphocytic Lymphoma, Recurrent Transformed Chronic Lymphocytic Leukemia, Refractory Chronic Lymphocytic Leukemia, Refractory Diffuse Large B-Cell Lymphoma, Refractory Follicular Lymphoma, Refractory Mantle Cell Lymphoma, Refractory Marginal Zone Lymphoma, Refractory Small Lymphocytic Lymphoma, Refractory Transformed Chronic Lymphocytic Leukemia
    View official trial listing →
  • Recruiting NCT NCT06241456

    FT825/ONO-8250, an Off-the-Shelf, HER2 CAR-T, With or Without Monoclonal Antibodies in Advanced Solid Tumors

    Not yet reported Fate Therapeutics 351 participants Est. completion 2044-05-01 14 sites Stand-alone
    Other conditions: Advanced Solid Tumor
    View official trial listing →
  • Recruiting NCT NCT06245629

    Bortezomib-bendamustine-melphalan vs Melphalan for Multiple Myeloma

    Uppsala University 100 participants Est. completion 2025-11-30 1 site
    Other conditions: Myeloma Multiple
    View official trial listing →
  • Recruiting NCT NCT06308978

    A Phase 1 Study of FT819 in B-cell Mediated Autoimmune Disease

    Not yet reported Fate Therapeutics 244 participants Est. completion 2042-09-30 21 sites Stand-alone
    Other conditions: Antineutrophilic Cytoplasmic Antibody (ANCA)- Associated Vasculitis (AAV), Idiopathic Inflammatory Myositis (IIM), Systemic Sclerosis (SSc), Systemic Lupus Erythematosus (SLE), Lupus Nephritis
    View official trial listing →
  • Recruiting NCT NCT06363994

    A Global Phase 3 Study of Orelabrutinib+BR Vs.BR in Pts with TN MCL

    Not yet reported InnoCare Pharma Inc. 476 participants Est. completion 2032-06-25 39 sites
    Other conditions: Mantle Cell Lymphoma
    View official trial listing →
  • Recruiting NCT NCT06477549

    BeFluBu vs FluBuRux Conditioning in Haploidentical HCT

    Not yet reported St. Petersburg State Pavlov Medical University 220 participants Est. completion 2029-06 1 site Stand-alone
    Other conditions: Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Biphenotypic Acute Leukemia, Lymphoblastic Lymphoma, Myeloproliferative Neoplasm, Myelodysplastic Syndromes
    View official trial listing →
  • Recruiting NCT NCT06482684

    CAR-T-cell Treatment for Untreated High Risk MANtle Cell Lymphoma

    Not yet reported Christian Schmidt, MD 150 participants Est. completion 2031-12-31 2 sites
    Other conditions: Mantle Cell Lymphoma
    View official trial listing →
  • Recruiting NCT NCT06483048

    MUC1-Activated T Cells for the Treatment of Relapsed and Resistant Ovarian Cancer

    Not yet reported Mayo Clinic 12 participants Est. completion 2028-09-30 1 site Stand-alone
    Obstructive sleep apnea Other conditions: Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Ovarian Carcinoma, Platinum-Resistant Primary Peritoneal Carcinoma, Recurrent Fallopian Tube Carcinoma, Recurrent Female Reproductive System Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Platinum-Resistant Fallopian Tube Carcinoma, Recurrent Platinum-Resistant Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma, Refractory Fallopian Tube Carcinoma, Refractory Female Reproductive System Carcinoma, Refractory Ovarian Carcinoma, Refractory Primary Peritoneal Carcinoma
    View official trial listing →
  • Recruiting NCT NCT06496308

    Bendamustine and Rituximab With or Without Orelabrutinib in MCL Treatment

    Not yet reported Ruijin Hospital 78 participants Est. completion 2027-07-10 1 site Stand-alone
    Other conditions: Mantle Cell Lymphoma (MCL)
    View official trial listing →
  • Recruiting NCT NCT06504940

    Optimize Study - Orelabrutinib Combined With BR/G in Untreated Marginal Zone Lymphoma (MZL)

    Not yet reported First Affiliated Hospital of Zhejiang University 69 participants Est. completion 2029-07-08 1 site Stand-alone
    Other conditions: Marginal Zone Lymphoma
    View official trial listing →
  • Recruiting NCT NCT06522737

    A Study of Duvelisib Versus Gemcitabine or Bendamustine in Participants With Relapsed/Refractory Nodal T Cell Lymphoma With T Follicular Helper (TFH) Phenotype

    Not yet reported SecuraBio 124 participants Est. completion 2028-12 44 sites
    Other conditions: Lymphoma
    View official trial listing →
  • Recruiting NCT NCT06532084

    Sorafenib Relapase Prophylaxis After HCT With PTBCy Regimen

    Not yet reported St. Petersburg State Pavlov Medical University 88 participants Est. completion 2028-05 1 site
    Other conditions: Acute Myeloid Leukemia, in Relapse, Myelodysplastic Syndromes, Chronic Myeloid Leukemia, Myeloproliferative Neoplasm
    View official trial listing →
  • Recruiting NCT NCT06549595

    A Study of Surovatamig (AZD0486) Plus Rituximab in Previously Untreated Follicular Lymphoma Patients

    Not yet reported AstraZeneca 1018 participants Est. completion 2031-11-26 235 sites
    Other conditions: Untreated Follicular Lymphoma
    View official trial listing →
  • Recruiting NCT NCT06554600

    A Study of Zanubrutinib in Combination With Polatuzumab Vedotin, Bendamustine and Rituximab in the Treatment of Relapsed/Refractory Diffuse Large B-cell Lymphoma

    Not yet reported Second Affiliated Hospital, Zhejiang University, School of Medicine 36 participants Est. completion 2028-08-31 1 site Stand-alone
    Other conditions: Refractory or Relapsed Diffuse Large B Cell Lymphoma
    View official trial listing →
  • Recruiting NCT NCT06561347

    Zanubrutinib, Bendamustine, Rituximab Prev. Untreated WM

    Not yet reported Massachusetts General Hospital 65 participants Est. completion 2027-12-01 5 sites Stand-alone
    Other conditions: Waldenstrom Macroglobulinemia
    View official trial listing →
  • Recruiting NCT NCT06846671

    A Study of Tacabrutideg (BGB-16673) Compared to Investigator's Choice in Participants With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Both Bruton Tyrosine Kinase (BTK) and B-cell Leukemia/Lymphoma 2 Protein (BCL2) Inhibitors

    Not yet reported BeOne Medicines 250 participants Est. completion 2030-02-14 132 sites
    Other conditions: CLL, Chronic Lymphocytic Leukemia
    View official trial listing →
  • Recruiting NCT NCT06854003

    BRAZAN: A Randomized Phase 2 Study of Bendamustine, Rituximab, Cytarabine (AraC) Induction With Zanubrutinib (BRAZAN) Followed by Zanubrutinib/Rituximab +/- Sonrotoclax Maintenance in Treatment-Naïve Mantle Cell Lymphoma

    Not yet reported Christine Ryan 60 participants Est. completion 2039-11-01 7 sites Stand-alone
    Other conditions: Mantle Cell Lymphoma, Lymphoma
    View official trial listing →
  • Recruiting NCT NCT06911502

    A Study to Compare the Efficacy and Safety of Golcadomide in Combination With Rituximab (Golca + R) vs Investigator's Choice in Participants With Relapsed/Refractory Follicular Lymphoma Who Have Received at Least 1 Prior Line of Systemic Therapy (GOLSEEK-4)

    Not yet reported Celgene 400 participants Est. completion 2030-07-31 160 sites
    Other conditions: Follicular Lymphoma
    View official trial listing →
  • Recruiting NCT NCT07059650

    DZD8586 Combination Therapy in Patients With Diffuse Large B-cell Lymphoma (TAI-SHAN12)

    Not yet reported, Not yet reported Dizal Pharmaceuticals 150 participants Est. completion 2030-10 13 sites Stand-alone
    Other conditions: Diffuse Large B-Cell Lymphoma
    View official trial listing →
  • Recruiting NCT NCT07072221

    Bendamustine Combined With Chidamide and Lenalidomide for Relapsed and Refractory PTCL Patients

    Not yet reported The First Affiliated Hospital of Soochow University 40 participants Est. completion 2029-11-01 1 site Stand-alone
    Other conditions: Peripheral T-cell Lymphoma
    View official trial listing →
  • Recruiting NCT NCT07126678

    Fixed-Duration Zanubrutinib, Bendamustine, and Obinutuzumab (ZBG) in Treatment-Naïve Advanced Stage Follicular Lymphoma

    Not yet reported The First Affiliated Hospital with Nanjing Medical University 15 participants Est. completion 2028-12-30 1 site Stand-alone
    Other conditions: Follicular Lymphoma, Treatment Naive
    View official trial listing →
  • Recruiting NCT NCT07139873

    A Study of DZD8586 Versus Investigator's Choice in r/r CLL/SLL (TAI-SHAN6)

    Not yet reported Dizal Pharmaceuticals 250 participants Est. completion 2029-12 2 sites
    Other conditions: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
    View official trial listing →
  • Recruiting NCT NCT07189065

    A Study of Rocbrutinib in Participants With Relapse or Refractory Non-GCB Diffuse Large B-Cell Lymphoma

    Not yet reported Guangzhou Lupeng Pharmaceutical Company LTD. 150 participants Est. completion 2028-12-31 41 sites
    Other conditions: Diffuse Large B-Cell Lymphoma (DLBCL)
    View official trial listing →
  • Recruiting NCT NCT07208981

    Orelabrutinib Combined With Zebetuzumab and Lenalidomide for the Treatment of Newly Diagnosed MZL

    Not yet reported The First Affiliated Hospital with Nanjing Medical University 169 participants Est. completion 2031-06-01 1 site
    Other conditions: Marginal Zone Lymphoma(MZL)
    View official trial listing →
  • Recruiting NCT NCT07225985

    Pralatrexate With Bendamustine and Total-Body Irradiation Followed by Donor Stem Cell Transplant for the Treatment of Relapsed or Refractory T-Cell Non-Hodgkin Lymphoma

    Not yet reported, Not yet reported Fred Hutchinson Cancer Center 50 participants Est. completion 2030-11-15 1 site Stand-alone
    Other conditions: Recurrent T-Cell Non-Hodgkin Lymphoma, Refractory T-Cell Non-Hodgkin Lymphoma
    View official trial listing →
  • Recruiting NCT NCT07238712

    Optimization of Post-transplantation Benadamustine and Cyclophosphamide in Patients With High-risk Myeloid Malignancies and a Partially Mismatched Donor

    Not yet reported St. Petersburg State Pavlov Medical University 60 participants Est. completion 2026-12-10 1 site Stand-alone
    Other conditions: Acute Myeloid Leukemia (AML), Chronic Myeloid Leukemia, Myelodysplastic Syndromes (MDS), Myeloprolipherative Neoplsm, Atypical Chronic Myeloid Leukemia
    View official trial listing →
  • Recruiting NCT NCT07477639

    Treatment of Participants With Primary or Secondary Progressive Multiple Sclerosis

    Not yet reported, Not yet reported Tr1X, Inc. 39 participants Est. completion 2029-01 8 sites Stand-alone
    Other conditions: Primary Progressive Multiple Sclerosis, Secondary Progressive Multiple Sclerosis (SPMS), Multiple Sclerosis, Multiple Sclerosis (MS) Primary Progressive, Multiple Sclerosis (MS) Secondary Progressive
    View official trial listing →
  • Recruiting NCT NCT07634471

    A Clinical Trial of MK-1045 and Rituximab in People With Follicular Lymphoma (MK-1045-007)

    Not yet reported, Not yet reported Merck Sharp & Dohme LLC 960 participants Est. completion 2035-07-23 32 sites Stand-alone
    Other conditions: Follicular Lymphoma
    View official trial listing →
  • Completed NCT NCT00069758

    Safety and Activity of SDX-105 (Bendamustine) in Patients With Rituximab Refractory Non-Hodgkin's Lymphoma

    Not yet reported Cephalon 72 participants Est. completion 2007-04 17 sites
    Other conditions: Non-Hodgkin's Lymphoma
    View official trial listing →
  • Completed NCT NCT00076349

    SDX-105 in Combination With Rituxan for Patients With Relapsed Indolent or Mantle Cell Non-Hodgkin's Lymphoma (NHL)

    Not yet reported Cephalon 66 participants Est. completion 2008-03 34 sites Stand-alone
    Other conditions: Non-Hodgkin's Lymphoma
    View official trial listing →
  • Completed NCT NCT00139841

    Safety and Efficacy of Treanda™ (Bendamustine HCl) in Patients With Indolent Non-Hodgkin's Lymphoma (NHL) Who Are Refractory to Rituximab

    Not yet reported Cephalon 103 participants Est. completion 2009-10 40 sites Stand-alone
    Other conditions: Non-Hodgkin's Lymphoma
    View official trial listing →
  • Status unknown NCT NCT00168922

    Study to Determine the Efficacy of Bendamustin in Patients With Recurrent Small Cell Lung Cancer (SCLC)

    Not yet reported Charite University, Berlin, Germany 50 participants Est. completion 2006-12 1 site
    Other conditions: Recurrent Small Cell Lung Cancer
    View official trial listing →
  • Completed NCT NCT00204620

    Bendamustin Hydrochloride in Patients With Soft Tissue Sarcoma (STS)

    Not yet reported University Hospital Tuebingen 28 participants Est. completion 2006-12 1 site
    Other conditions: Sarcoma, Soft Tissue
    View official trial listing →
  • Completed NCT NCT00274963

    Bendamustine and Mitoxantrone in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia

    Not yet reported German CLL Study Group 60 participants Est. completion 2009-10 12 sites
    Other conditions: Chronic Lymphocytic Leukemia
    View official trial listing →
  • Completed NCT NCT00274989

    Bendamustine and Rituximab in Treating Patients With Previously Untreated or Relapsed Chronic Lymphocytic Leukemia

    Not yet reported German CLL Study Group 195 participants Est. completion 2011-03 58 sites Stand-alone
    Other conditions: Chronic Lymphocytic Leukemia
    View official trial listing →
  • Status unknown NCT NCT00385125

    Treatment of Patients With Relapsed or Primary Refractory Aggressive B- Cell NHL

    Not yet reported University of Magdeburg 30 participants Est. completion 2010-08 1 site
    Other conditions: Lymphoma, High-Grade
    View official trial listing →
  • Completed NCT NCT00389051

    A Phase I Study of Bendamustine Hydrochloride in Patients With Indolent B-cell Non-Hodgkin's Lymphoma

    Not yet reported SymBio Pharmaceuticals 9 participants Est. completion 2007-10-26 4 sites
    Other conditions: Non-Hodgkin's Lymphoma
    View official trial listing →
  • Completed NCT NCT00426855

    Bendamustine and Bortezomib Combination Therapy in Indolent Non-Hodgkin's Lymphoma(NHL)

    Not yet reported, Not yet reported Peter Moosmann 12 participants Est. completion 2009-06 Stand-alone
    Other conditions: Lymphoma, Non-Hodgkin
    View official trial listing →
  • Completed NCT NCT00547534

    Pilot Study of Bortezomib, Bendamustine and Rituximab on Non-Hodgkin's Lymphoma

    Not yet reported University of Rochester 31 participants Est. completion 2009-10 3 sites Stand-alone
    Other conditions: Non-Hodgkin's Lymphoma
    View official trial listing →
  • Completed NCT NCT00612183

    Clinical Study on SyB L-0501 in Patients With Indolent B-cell Non-Hodgkin's Lymphoma or Mantle Cell Lymphoma

    Not yet reported SymBio Pharmaceuticals 56 participants Est. completion 2009-09 17 sites
    Other conditions: Non-Hodgkin's Lymphoma, Mantle Cell Lymphoma
    View official trial listing →
  • Completed NCT NCT00634881

    Alemtuzumab in Treating Patients With B-Cell Chronic Lymphocytic Leukemia

    Not yet reported, Not yet reported German CLL Study Group 13 participants Est. completion 2012-02-17 6 sites
    Other conditions: Chronic Lymphocytic Leukemia
    View official trial listing →
  • Completed NCT NCT00636792

    A Phase II Study of VELCADE (Bortezomib) in Combination With Bendamustine and Rituximab in Subjects With Relapsed or Refractory Follicular Lymphoma

    Not yet reported Millennium Pharmaceuticals, Inc. 73 participants Est. completion 2010-05 2 sites Stand-alone
    Other conditions: Follicular Lymphoma
    View official trial listing →
  • Completed NCT NCT00661739

    A Multicentre Phase I-II Study to Investigate the Combination of Bendamustine With Weekly Paclitaxel as First or Second Line Therapy in Patients With Metastatic Breast Cancer

    Not yet reported GBG Forschungs GmbH 38 participants Est. completion 2011-05 Stand-alone
    Other conditions: Metastatic Breast Cancer
    View official trial listing →
  • Completed NCT NCT00705250

    Bendamustine HCL in Relapsed and Primary Refractory Hodgkin Lymphoma

    Not yet reported Memorial Sloan Kettering Cancer Center 36 participants Est. completion 2015-12 1 site Stand-alone
    Other conditions: Hodgkin's Disease, Lymphoma
    View official trial listing →
  • Completed NCT NCT00740415

    Rituximab, Bortezomib,Bendamustine , Dexamethasone, Patients With Mantle Cell Lymphoma

    Not yet reported French Innovative Leukemia Organisation 39 participants Est. completion 2015-08 1 site Stand-alone
    Other conditions: Lymphoma
    View official trial listing →
  • Withdrawn NCT NCT00758693

    Frontline Treatment With Bendamustine in Combination With Rituximab in Adults Age 65 or Older With Chronic Lymphocytic Leukemia (CLL)

    Not yet reported University of Kentucky Est. completion 2010-07 1 site Stand-alone
    Other conditions: Chronic Lymphocytic Leukemia
    View official trial listing →
  • Completed NCT NCT00769522

    FCR or BR in Patients With Previously Untreated B-Cell Chronic Lymphocytic Leukemia

    Not yet reported German CLL Study Group 564 participants Est. completion 2018-01 1 site Stand-alone
    Other conditions: Chronic Lymphocytic Leukemia
    View official trial listing →
  • Terminated NCT NCT00790855

    Bendamustine in Acute Leukemia and MDS

    Not yet reported, Not yet reported M.D. Anderson Cancer Center 27 participants Est. completion 2012-03 1 site Stand-alone
    Other conditions: Acute Myeloid Leukemia, Myelodysplastic Syndrome, Acute Lymphoblastic Leukemia, Chronic Myeloid Leukemia
    View official trial listing →
  • Completed NCT NCT00794638

    A Phase I Clinical Trial of SyB L-0501 in Combination With Rituximab to Patients With Aggressive B-cell Non-Hodgkin's Lymphoma

    Not yet reported SymBio Pharmaceuticals 9 participants Est. completion 2010-05 4 sites
    Other conditions: Non-Hodgkin's Lymphoma, Diffuse Large B-Cell Lymphoma, Mantle Cell Lymphoma, Follicular Lymphoma
    View official trial listing →
  • Completed NCT NCT00823797

    Bendamustine Hydrochloride in Treating Patients With Recurrent or Progressive Anaplastic Glioma

    Not yet reported University of Washington 45 participants Est. completion 2017-04 3 sites Stand-alone
    Obstructive sleep apnea Other conditions: Adult Anaplastic Astrocytoma, Adult Anaplastic Oligodendroglioma, Adult Giant Cell Glioblastoma, Adult Glioblastoma, Recurrent Adult Brain Neoplasm
    View official trial listing →
  • Completed NCT NCT00825149

    A Study of Obinutuzumab in Combination With Chemotherapy in Participants With CD20+ B-Cell Follicular Non-Hodgkin's Lymphoma

    Not yet reported Hoffmann-La Roche 137 participants Est. completion 2015-11 34 sites Stand-alone
    Other conditions: Non-Hodgkin's Lymphoma
    View official trial listing →
  • Completed NCT NCT00831597

    Bendamustine Combined With Rituximab for Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma

    Not yet reported Pharmatech 61 participants Est. completion 2013-09 33 sites Stand-alone
    Other conditions: Diffuse Large B-Cell Lymphoma
    View official trial listing →
  • Completed NCT NCT00834678

    Bendamustine and Erlotinib in Treating Patients With Stage IIIB, Stage IIIC, or Stage IV Breast Cancer

    Not yet reported, Not yet reported Ohio State University Comprehensive Cancer Center 11 participants Est. completion 2014-09 1 site Stand-alone
    Other conditions: Breast Cancer
    View official trial listing →
  • Completed NCT NCT00837928

    Bendamustine and Radiation Therapy in Treating Patients With Brain Metastases Caused by Solid Tumors

    Not yet reported John Grecula 18 participants Est. completion 2015-01-08 1 site Stand-alone
    Other conditions: Metastatic Cancer, Unspecified Adult Solid Tumor, Protocol Specific
    View official trial listing →
  • Completed NCT NCT00856830

    Bendamustine With Irinotecan Followed by Etoposide/Carboplatin for Patients With Extensive Stage Small Cell Lung Cancer

    Not yet reported, Not yet reported University of Alabama at Birmingham 30 participants Est. completion 2016-05 2 sites Stand-alone
    Other conditions: Small Cell Lung Cancer, Extensive Stage Lung Cancer, Chemonaive
    View official trial listing →
  • Completed NCT NCT00863850

    Pharmacokinetics of Bendamustine Hydrochloride in Patients With Relapsed or Refractory Malignancy

    Not yet reported Cephalon 6 participants Est. completion 2010-03 1 site Stand-alone
    Other conditions: Malignancy
    View official trial listing →
  • Completed NCT NCT00864942

    Trial of Bendamustine, Lenalidomide and Rituximab in Chronic Lymphocytic Leukemia (CLL) and Non-Hodgkin's Lymphoma (NHL)

    Not yet reported Georgetown University 28 participants Est. completion 2014-10 1 site Stand-alone
    Other conditions: Chronic Lymphocytic Leukemia, Non-Hodgkin's Lymphoma
    View official trial listing →
  • Completed NCT NCT00867503

    Open Trial of Bendamustine Hydrochloride in Women With Advanced Ovarian Cancer

    Not yet reported University of Arizona 10 participants Est. completion 2013-04 1 site Stand-alone
    Other conditions: Ovarian Cancer
    View official trial listing →
  • Completed NCT NCT00868413

    Study of ABT-263 When Administered in Combination With Either Fludarabine/Cyclophosphamide/Rituximab or Bendamustine/Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia

    Not yet reported AbbVie (prior sponsor, Abbott) 32 participants Est. completion 2013-05 6 sites
    Other conditions: Chronic Lymphocytic Leukemia
    View official trial listing →
  • Withdrawn NCT NCT00872976

    Study of Dasatinib and Bendamustine in Chronic Lymphocytic Leukemia

    Not yet reported Bristol-Myers Squibb Est. completion 2011-12 3 sites Stand-alone
    Other conditions: Chronic Lymphocytic Leukemia
    View official trial listing →
  • Completed NCT NCT00877006

    Study of Bendamustine Hydrochloride and Rituximab (BR) Compared With R-CVP or R-CHOP in the First-Line Treatment of Patients With Advanced Indolent Non-Hodgkin's Lymphoma (NHL) or Mantle Cell Lymphoma (MCL) - Referred to as the BRIGHT Study

    Not yet reported Teva Branded Pharmaceutical Products R&D, Inc. 447 participants Est. completion 2012-03-31 128 sites Stand-alone
    Other conditions: Non-Hodgkin's Lymphoma, Mantle Cell Lymphoma
    View official trial listing →
  • Status unknown NCT NCT00877214

    Significance of Duration of Maintenance Therapy With Rituximab in Non-Hodgkin Lymphomas

    Not yet reported Jurgen Barth 1272 participants Est. completion 2024-12 1 site Stand-alone
    Other conditions: Follicular Lymphomas, Immunocytomas, Marginal Zone Lymphomas, Mantle-Cell Lymphomas, Lymphocytic Lymphoma, Non-Hodgkin's Lymphoma
    View official trial listing →
  • Terminated NCT NCT00879073

    Study Bendamustine Concurrent Whole Brain Radiation Brain Metastases From Solid Tumors

    Not yet reported H. Lee Moffitt Cancer Center and Research Institute 12 participants Est. completion 2012-12 1 site Stand-alone
    Other conditions: Brain Metastases
    View official trial listing →
  • Completed NCT NCT00880815

    Fludarabine, Bendamustine, and Rituximab in Treating Participants With Lymphoid Cancers Undergoing Stem Cell Transplant

    Not yet reported M.D. Anderson Cancer Center 60 participants Est. completion 2019-05-28 1 site Stand-alone
    Other conditions: CD20 Positive, Chronic Lymphocytic Leukemia, Follicular Lymphoma, Mantle Cell Lymphoma, Marginal Zone Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, T-Cell Non-Hodgkin Lymphoma
    View official trial listing →
  • Completed NCT NCT00889798

    Tumor Registry of Lymphatic Neoplasia

    iOMEDICO AG 3795 participants Est. completion 2019-08-31
    Other conditions: Non-Hodgkin's Lymphoma (NHL), Chronic Lymphocytic Leukemia (CLL), Multiple Myeloma (MM)
    View official trial listing →
  • Completed NCT NCT00891839

    Bendamustine Hydrochloride in Combination With Rituximab in Patients With Relapsed Refractory Mantle Cell Lymphoma

    Not yet reported Cephalon 45 participants Est. completion 2014-05 13 sites Stand-alone
    Other conditions: Mantle Cell Lymphoma
    View official trial listing →
  • Terminated NCT NCT00899431

    Nonmyeloablative Stem Cell Transplantation for Chronic Lymphocytic Leukemia (CLL)

    Not yet reported M.D. Anderson Cancer Center 39 participants Est. completion 2018-10-07 1 site
    Other conditions: Chronic Lymphocytic Leukemia
    View official trial listing →
  • Terminated NCT NCT00901927

    Bendamustine, Mitoxantrone, and Rituximab (BMR) for Patients With Untreated High Risk Follicular Lymphoma

    Not yet reported M.D. Anderson Cancer Center 14 participants Est. completion 2016-01 1 site Stand-alone
    Other conditions: Follicular Lymphoma
    View official trial listing →
  • Completed NCT NCT00916058

    Conditioning Regimen of Bendamustine and Melphalan Followed by Transplant in Patients With Multiple Myeloma

    Not yet reported, Not yet reported Weill Medical College of Cornell University 57 participants Est. completion 2018-03-01 1 site Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Completed NCT NCT00920855

    Study of Bendamustine Combined With Bortezomib for Patients With Relapsed/Refractory Multiple Myeloma

    Not yet reported, Not yet reported Cephalon 40 participants Est. completion 2011-12 13 sites Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Withdrawn NCT NCT00939328

    S0902 Bendamustine and Rituximab in Treating Patients With B-Cell Chronic Lymphocytic Leukemia That Has Not Responded to Previous Treatment

    Not yet reported SWOG Cancer Research Network Est. completion 2010-09
    Other conditions: Leukemia
    View official trial listing →
  • Terminated NCT NCT00947388

    Bendamustine Plus Alemtuzumab for Refractory Chronic Lymphocytic Leukemia (CLL)

    Not yet reported Case Comprehensive Cancer Center 9 participants Est. completion 2013-03 2 sites Stand-alone
    Other conditions: Recurrent Small Lymphocytic Lymphoma, Refractory Chronic Lymphocytic Leukemia, Stage III Chronic Lymphocytic Leukemia, Stage III Small Lymphocytic Lymphoma, Stage IV Chronic Lymphocytic Leukemia, Stage IV Small Lymphocytic Lymphoma
    View official trial listing →
  • Completed NCT NCT00951457

    Bendamustine Combined With Alemtuzumab in Pretreated Chronic Lymphocytic Leukemia (CLL)

    Not yet reported, Not yet reported Arbeitsgemeinschaft medikamentoese Tumortherapie 20 participants Est. completion 2012-08-06 7 sites Stand-alone
    Other conditions: Leukemia, Lymphocytic, Chronic, B-Cell
    View official trial listing →
  • Completed NCT NCT00959686

    Bendamustine in Patients With Refractory or Relapsed T-cell Lymphoma

    Not yet reported French Innovative Leukemia Organisation 45 participants Est. completion 2013-02 1 site Stand-alone
    Other conditions: T-cell Lymphoma
    View official trial listing →
  • Completed NCT NCT00963534

    Lenalidomide, Bendamustine and Rituximab as First-line Therapy for Patients Over 65 Years With Mantle Cell Lymphoma.

    Not yet reported, Not yet reported Lund University Hospital 51 participants Est. completion 2017-08 17 sites Stand-alone
    Other conditions: Mantle Cell Lymphoma
    View official trial listing →
  • Completed NCT NCT00974233

    Study of Bendamustine/Rituxan Induction Chemotherapy With Revlimid Maintenance for Relapsed/Refractory CLL and SLL

    Not yet reported University of Wisconsin, Madison 34 participants Est. completion 2015-04 10 sites Stand-alone
    Other conditions: Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
    View official trial listing →
  • Completed NCT NCT00984542

    Bendamustine as Second-Line Therapy in Treating Patients With Relapsed or Refractory Small Cell Lung Cancer

    Not yet reported Vanderbilt-Ingram Cancer Center 50 participants Est. completion 2012-09 6 sites Stand-alone
    Other conditions: Lung Cancer
    View official trial listing →
  • Completed NCT NCT00987493

    Rituximab, Bendamustine Hydrochloride, and Lenalidomide in Treating Patients With Aggressive B-Cell Lymphoma

    Not yet reported, Not yet reported Swiss Cancer Institute 49 participants Est. completion 2016-04 16 sites Stand-alone
    Other conditions: Lymphoma
    View official trial listing →
  • Completed NCT NCT00991211

    Bendamustine Plus Rituximab Versus CHOP Plus Rituximab

    Not yet reported University of Giessen 549 participants Est. completion 2009-08 1 site Stand-alone
    Other conditions: Non-Hodgkin Lymphomas, Follicular Lymphomas, Immunocytomas, Lymphocytic Lymphomas, Marginal Zone Lymphomas
    View official trial listing →
  • Completed NCT NCT00992134

    Immunochemotherapy With Rituximab-Bendamustine-Cytarabine (R-BAC) for Patients With Mantle Cell Lymphoma

    Not yet reported St. Bortolo Hospital 41 participants Est. completion 2012-06 1 site
    Other conditions: Lymphoma, Mantle-Cell
    View official trial listing →
  • Status unknown NCT NCT01002703

    Treatment With Lenalidomide, Bendamustine and Prednisone (RBP) in Patients With Relapsed or Refractory Multiple Myeloma

    Not yet reported, Not yet reported University of Leipzig 50 participants Est. completion 2014-10 1 site Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Terminated NCT NCT01010568

    Ofatumumab and Bendamustine for Previously Treated Chronic Lymphocytic Leukemia (CLL)

    Not yet reported Georgetown University 10 participants Est. completion 2014-08 1 site Stand-alone
    Other conditions: Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
    View official trial listing →
  • Completed NCT NCT01015248

    Trial of Bendamustine And Rituximab for Patients With Previously Untreated Extranodal Mucosa-Associated Lymphoid Tissue (MALT) Lymphoma

    Not yet reported Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea 60 participants Est. completion 2013-12 19 sites Stand-alone
    Other conditions: MALT LYMPHOMA
    View official trial listing →
  • Completed NCT NCT01022021

    Peripheral Blood Stem Cell (PBSC) Mobilization in Patients With Relapsed Lymphoma Treated With Bendamustine

    Not yet reported University of Kansas Medical Center 17 participants Est. completion 2015-08 1 site
    Other conditions: Lymphoma
    View official trial listing →
  • Completed NCT NCT01029730

    Trial of Bendamustine, Bortezomib, and Rituximab in Patients With Previously Untreated Low Grade Lymphoma

    Not yet reported SCRI Development Innovations, LLC 55 participants Est. completion 2016-07 20 sites Stand-alone
    Other conditions: Lymphoma
    View official trial listing →
  • Completed NCT NCT01042704

    Bendamustine in Combination With Lenalidomide and Dexamethasone in Refractory or Relapsed Multiple Myeloma

    Not yet reported Robert Redner, MD 29 participants Est. completion 2015-03 22 sites Stand-alone
    Other conditions: Myeloma
    View official trial listing →
  • Completed NCT NCT01045681

    Study of Bendamustine, Velcade and Dexamethasone in the Treatment of Elderly Patients With Multiple Myeloma

    Not yet reported Intergroupe Francophone du Myelome 75 participants Est. completion 2013-03-28 37 sites Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Completed NCT NCT01049945

    Bendamustine Hydrochloride, Lenalidomide, and Dexamethasone in Treating Patients With Relapsed Multiple Myeloma

    Not yet reported, Not yet reported Mayo Clinic 70 participants Est. completion 2015-09-16 5 sites Stand-alone
    Other conditions: Refractory Multiple Myeloma
    View official trial listing →
  • Completed NCT NCT01056276

    Study to Evaluate the Combination of Bendamustine, Bortezomib and Dexamethasone (BBD) in the First-Line Treatment of Patients With Multiple Myeloma Who Are Not Candidates for High Dose Chemotherapy

    Not yet reported SCRI Development Innovations, LLC 59 participants Est. completion 2017-02 13 sites Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Completed NCT NCT01056510

    A Study of MabThera Added to Bendamustine or Chlorambucil in Patients With Chronic Lymphocytic Leukemia (MaBLe)

    Not yet reported Hoffmann-La Roche 357 participants Est. completion 2014-03 85 sites Stand-alone
    Other conditions: Lymphocytic Leukemia, Chronic
    View official trial listing →
  • Completed NCT NCT01059630

    A Study to Investigate the Efficacy and Safety of Bendamustine Compared With Bendamustine+Obinutuzumab (GA101) in Participants With Rituximab-Refractory, Indolent Non-Hodgkin's Lymphoma (GADOLIN)

    Not yet reported Genentech, Inc. 413 participants Est. completion 2018-11-30 121 sites Stand-alone
    Other conditions: Non-Hodgkin's Lymphoma
    View official trial listing →
  • Active, not recruiting NCT NCT01059786

    Randomized Phase II Trial of Rituximab With Either Pentostatin or Bendamustine for Multiply Relapsed or Refractory Hairy Cell Leukemia

    Not yet reported National Cancer Institute (NCI) 69 participants Est. completion 2031-06-30 1 site Stand-alone
    Other conditions: Hairy Cell Leukemia
    View official trial listing →
  • Completed NCT NCT01073163

    Study to Assess the Effect of Treatment With Bendamustine in Combination With Rituximab on QT Interval in Patients With Advanced Indolent Non-Hodgkin's Lymphoma (NHL) or Mantle Cell Lymphoma (MCL)

    Not yet reported Cephalon 54 participants Est. completion 2012-06 43 sites Stand-alone
    Other conditions: Non-Hodgkin's Lymphoma, Mantle Cell Lymphoma
    View official trial listing →
  • Terminated NCT NCT01077518

    Ofatumumab Bendamustine Combination Compared With Bendamustine Monotherapy in Indolent B-cell NHL Unresponsive to Rituxtherapy

    Not yet reported Novartis Pharmaceuticals 346 participants Est. completion 2018-12-26 140 sites Stand-alone
    Other conditions: Lymphoma, Follicular
    View official trial listing →
  • Completed NCT NCT01078142

    Temsirolimus, Bendamustine and Rituximab for Relapsed Follicular Lymphoma or Mantle Cell Lymphoma

    Not yet reported, Not yet reported Georg Hess, MD 39 participants Est. completion 2017-09-08 1 site
    Other conditions: Follicular Lymphoma, Mantle Cell Lymphoma
    View official trial listing →
  • Completed NCT NCT01088048

    Study to Investigate Idelalisib in Combination With Chemotherapeutic Agents, Immunomodulatory Agents and Anti-CD20 Monoclonal Antibody (mAb) in Participants With Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma, Mantle Cell Lymphoma or Chronic Lymphocytic Leukemia

    Not yet reported Gilead Sciences 241 participants Est. completion 2015-04-28 11 sites Stand-alone
    Other conditions: Indolent Non-Hodgkin's Lymphoma, Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma
    View official trial listing →
  • Completed NCT NCT01088984

    Study of Bendamustine Hydrochloride for the Treatment of Pediatric Patients With Relapsed or Refractory Acute Leukemia

    Not yet reported, Not yet reported Teva Branded Pharmaceutical Products R&D, Inc. 43 participants Est. completion 2011-08 50 sites Stand-alone
    Other conditions: Leukemia
    View official trial listing →
  • Completed NCT NCT01096992

    Fludarabine, Bendamustine, and Rituximab (FBR) for Relapsed Chronic Lymphocytic Leukemia (CLL)

    Not yet reported, Not yet reported M.D. Anderson Cancer Center 51 participants Est. completion 2017-03-31 1 site Stand-alone
    Other conditions: Leukemia
    View official trial listing →
  • Completed NCT NCT01108341

    Study to Evaluate the Efficacy and Safety of Treatment With Bendamustine in Combination With Ofatumumab in Previously Untreated Patients With Indolent B-Cell Non-Hodgkin's Lymphoma (NHL)

    Not yet reported Cephalon 50 participants Est. completion 2011-10 39 sites Stand-alone
    Other conditions: Non-Hodgkin's Lymphoma (NHL)
    View official trial listing →
  • Completed NCT NCT01109264

    Bendamustine Hydrochloride Injection for Initial Treatment of Chronic Lymphocytic Leukemia

    Not yet reported Jiangsu Simcere Pharmaceutical Co., Ltd. 147 participants Est. completion 2013-08 1 site Stand-alone
    Other conditions: Chronic Lymphocytic Leukemia
    View official trial listing →
  • Completed NCT NCT01110135

    Bendamustine Hydrochloride, Etoposide, Dexamethasone, and Filgrastim For Peripheral Blood Stem Cell Mobilization in Treating Patients With Refractory or Recurrent Lymphoma or Multiple Myeloma

    Not yet reported University of Washington 43 participants 1 site Stand-alone
    Obstructive sleep apnea Other conditions: Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma, Cutaneous B-cell Non-Hodgkin Lymphoma, Intraocular Lymphoma, Nodal Marginal Zone B-cell Lymphoma, Peripheral T-cell Lymphoma, Recurrent Adult Burkitt Lymphoma, Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Adult Diffuse Mixed Cell Lymphoma, Recurrent Adult Diffuse Small Cleaved Cell Lymphoma, Recurrent Adult Grade III Lymphomatoid Granulomatosis, Recurrent Adult Hodgkin Lymphoma, Recurrent Adult Immunoblastic Large Cell Lymphoma, Recurrent Adult Lymphoblastic Lymphoma, Recurrent Adult T-cell Leukemia/Lymphoma, Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Grade 3 Follicular Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Marginal Zone Lymphoma, Recurrent Mycosis Fungoides/Sezary Syndrome, Recurrent Small Lymphocytic Lymphoma, Refractory Multiple Myeloma, Small Intestine Lymphoma, Splenic Marginal Zone Lymphoma, Waldenström Macroglobulinemia
    View official trial listing →
  • Completed NCT NCT01118845

    Study of SyB L-0501 in Combination With Rituximab to Treat Relapsed/Refractory Diffuse Large B-Cell Lymphoma

    Not yet reported SymBio Pharmaceuticals 63 participants Est. completion 2011-10 25 sites
    Other conditions: Non-Hodgkin's Lymphoma, Lymphoma, Large Cell, Diffuse, Mantle Cell Lymphoma, Lymphoma, Follicular Lymphoma, Large B-Cell, Diffuse
    View official trial listing →
  • Terminated NCT NCT01125787

    Clinical Protocol for the Treatment of Patients With Previously Untreated Chronic Lymphocytic Leukemia With a Combination of Bendamustine and Ofatumumab

    Not yet reported Nevada Cancer Institute 1 participants Est. completion 2011-04 2 sites Stand-alone
    Other conditions: Chronic Lymphocytic Leukemia (CLL)
    View official trial listing →
  • Status unknown NCT NCT01127841

    Trial of Rituximab, Bendamustine (RB) for Patients With Follicular Lymphoma Refractory or Relapsed After Treatment With R-chemotherapy in First Line

    Not yet reported Grupo Oncológico para el Tratamiento y el Estudio de los Linfomas 60 participants Est. completion 2015-12 18 sites Stand-alone
    Other conditions: Follicular Non-Hodgking´s Lymphoma Refractory or Relapsed After Treatment With R-chemotherapy in First Line.
    View official trial listing →
  • Withdrawn NCT NCT01131247

    PH2 Trial in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) With a Combination of Bendamustine & Ofatumumab

    Not yet reported Nevada Cancer Institute 37 participants 1 site Stand-alone
    Other conditions: Chronic Lymphocytic Leukemia (CLL)
    View official trial listing →
  • Completed NCT NCT01133158

    R-BMD in Refractory or Relapsed Lymphoma, GELTAMO Clinical Trial

    Not yet reported Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea 61 participants Est. completion 2016-07 41 sites Stand-alone
    Other conditions: Non-Hodgkin's Lymphoma
    View official trial listing →
  • Completed NCT NCT01141725

    Bendamustine and Idarubicin in Treating Older Patients With Previously Untreated AML or MDS

    Not yet reported, Not yet reported Fred Hutchinson Cancer Center 39 participants Est. completion 2012-11 1 site Stand-alone
    Other conditions: Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q), Adult Acute Myeloid Leukemia With Inv(16)(p13;q22), Adult Acute Myeloid Leukemia With t(15;17)(q22;q12), Adult Acute Myeloid Leukemia With t(16;16)(p13;q22), Adult Acute Myeloid Leukemia With t(8;21)(q22;q22), de Novo Myelodysplastic Syndromes, Myelodysplastic Syndrome With Isolated Del(5q), Untreated Adult Acute Myeloid Leukemia
    View official trial listing →
  • Completed NCT NCT01152203

    Bendamustine and Bevacizumab for Advanced Cancers

    Not yet reported M.D. Anderson Cancer Center 59 participants Est. completion 2014-05 1 site Stand-alone
    Other conditions: Advanced Cancer
    View official trial listing →
  • Completed NCT NCT01165112

    Bendamustine Hydrochloride, Rituximab, Etoposide, and Carboplatin in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma or Hodgkin Lymphoma

    Not yet reported, Not yet reported University of Washington 48 participants Est. completion 2015-06 1 site Stand-alone
    Other conditions: Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Adult Hodgkin Lymphoma
    View official trial listing →
  • Completed NCT NCT01168804

    Bendamustine Plus Bortezomib Plus Dexamethasone in Relapsed or Refractory Multiple Myeloma

    Not yet reported Austrian Forum Against Cancer 79 participants Est. completion 2013-05 8 sites Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Withdrawn NCT NCT01170052

    Bendamustine and Temsirolimus in Patients With Relapsed or Refractory Mantle Cell Non-Hodgkin's Lymphoma (NHL)

    Not yet reported, Not yet reported Charite University, Berlin, Germany 20 participants Est. completion 2014-04 3 sites
    Other conditions: Mantle Cell Lymphoma
    View official trial listing →
  • Terminated NCT NCT01177683

    Bendamustine in Combination With Bortezomib and Pegylated Liposomal Doxorubicin for Multiple Myeloma

    Not yet reported, Not yet reported Sherif Farag, MB, BS 32 participants Est. completion 2017-12 7 sites Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Terminated NCT NCT01179490

    Efficacy and Safety Study of SyB L-0501 for Patients With Multiple Myeloma

    Not yet reported SymBio Pharmaceuticals 5 participants 3 sites
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Completed NCT NCT01188681

    Safety and Efficacy Study of TRU-016 Plus Bendamustine vs. Bendamustine in Relapsed Chronic Lymphocytic Leukemia

    Not yet reported, Not yet reported Aptevo Therapeutics 79 participants Est. completion 2014-12 25 sites Stand-alone
    Other conditions: Chronic Lymphocytic Leukemia (CLL)
    View official trial listing →
  • Completed NCT NCT01216683

    Bendamustine Hydrochloride and Rituximab With or Without Bortezomib Followed by Rituximab With or Without Lenalidomide in Treating Patients With High-Risk Stage II, Stage III, or Stage IV Follicular Lymphoma

    Not yet reported ECOG-ACRIN Cancer Research Group 289 participants Est. completion 2019-12-02 227 sites Stand-alone
    Other conditions: Lymphoma
    View official trial listing →
  • Status unknown NCT NCT01221103

    Dexamethasone, Ofatumumab and Bendamustine (DOT) First-line in Mantle-cell Lymphoma(MCL)

    Not yet reported, Not yet reported Southern Europe New Drug Organization 50 participants Est. completion 2012-06 2 sites Stand-alone
    Other conditions: Lymphoma, Mantle-Cell
    View official trial listing →
  • Completed NCT NCT01222260

    Bendamustine and Dexamethasone in Patients With Relapsed AL Amyloidosis

    Not yet reported Columbia University 40 participants Est. completion 2019-07-03 6 sites Stand-alone
    Other conditions: AL Amyloidosis
    View official trial listing →
  • Completed NCT NCT01224769

    Bendamustine and Rituximab As Salvage Therapy In Patients With Chronic Lymphoproliferative Disorders

    Gruppo Italiano Studio Linfomi 109 participants Est. completion 2009-12 1 site
    Other conditions: Relapsed or Refractory Chronic Lymphoproliferative Disorders
    View official trial listing →
  • Terminated NCT NCT01232556

    A Study Of Inotuzumab Ozogamicin Plus Rituximab For Relapsed/Refractory Aggressive Non-Hodgkin Lymphoma Patients Who Are Not Candidates For Intensive High-Dose Chemotherapy

    Not yet reported Pfizer 338 participants Est. completion 2014-03-28 177 sites
    Other conditions: Lymphoma, Non-Hodgkin
    View official trial listing →
  • Completed NCT NCT01234467

    Bendamustine + Rituximab in Older Patients With Previously Untreated Diffuse Large B-cell Lymphoma

    Not yet reported UNC Lineberger Comprehensive Cancer Center 23 participants Est. completion 2016-08 7 sites Stand-alone
    Other conditions: Diffuse Large B-Cell Lymphoma, Lymphoma, Diffuse Large-Cell, Diffuse Large-Cell Lymphoma, Lymphoma
    View official trial listing →
  • Completed NCT NCT01234766

    Bendamustine and Rituximab Followed by 90-yttrium (Y) Ibritumomab Tiuxetan for Untreated Follicular Lymphoma

    Not yet reported Dartmouth-Hitchcock Medical Center 39 participants Est. completion 2021-04-01 4 sites Stand-alone
    Other conditions: Lymphoma, Follicular
    View official trial listing →
  • Withdrawn NCT NCT01238146

    Obatoclax Mesylate, Rituximab, and Bendamustine Hydrochloride in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma

    Not yet reported, Not yet reported National Cancer Institute (NCI) 1 site Stand-alone
    Obstructive sleep apnea Other conditions: Nodal Marginal Zone B-cell Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Marginal Zone Lymphoma, Splenic Marginal Zone Lymphoma
    View official trial listing →
  • Completed NCT NCT01244451

    GIMEMA CLL0809 Study (BendOfa)

    Not yet reported Gruppo Italiano Malattie EMatologiche dell'Adulto 49 participants Est. completion 2014-07 32 sites Stand-alone
    Other conditions: Patients With CLL Relapsing After an Initial Response (CR, PR ≥ 6 Months) Following no More Than Two Prior Treatment Lines; or, Patients With CLL Refractory (SD, PD or CR/PR < 6 Months) Following no More Than Two Prior Treatment Lines
    View official trial listing →
  • Completed NCT NCT01275209

    Study of HCD122 (Lucatumumab) and Bendamustine Combination Therapy in CD40+ Rituximab-refractory Follicular Lymphoma

    Not yet reported Novartis Pharmaceuticals 1 participants Est. completion 2012-05 12 sites
    Other conditions: Follicular Lymphoma
    View official trial listing →
  • Completed NCT NCT01286272

    Ofatumumab and Bendamustine Hydrochloride With or Without Bortezomib in Treating Patients With Untreated Follicular Non-Hodgkin Lymphoma

    Not yet reported National Cancer Institute (NCI) 135 participants Est. completion 2025-09-02 96 sites Stand-alone
    Other conditions: Ann Arbor Stage III Grade 1 Follicular Lymphoma, Ann Arbor Stage III Grade 2 Follicular Lymphoma, Ann Arbor Stage III Grade 3 Follicular Lymphoma, Ann Arbor Stage IV Grade 1 Follicular Lymphoma, Ann Arbor Stage IV Grade 2 Follicular Lymphoma, Ann Arbor Stage IV Grade 3 Follicular Lymphoma, Grade 3a Follicular Lymphoma
    View official trial listing →
  • Terminated NCT NCT01289223

    A Trial to Investigate the Efficacy of Bendamustine in Patients With Indolent Non-Hodgkin's Lymphoma (NHL) Refractory to Rituximab.

    Not yet reported Mundipharma Research Limited 88 participants Est. completion 2018-07-31 3 sites Stand-alone
    Other conditions: Indolent B-cell NHL
    View official trial listing →
  • Completed NCT NCT01292135

    Safety and Tolerability Study of PCI-32765 Combined With Fludarabine/Cyclophosphamide/Rituximab (FCR) and Bendamustine/Rituximab (BR) in Chronic Lymphocytic Leukemia (CLL)

    Not yet reported Pharmacyclics LLC. 33 participants Est. completion 2013-05 6 sites Stand-alone
    Other conditions: B-cell Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
    View official trial listing →
  • Completed NCT NCT01294579

    Ofatumumab and Bendamustine Followed by Maintenance Ofatumumab for Rituximab Relapsed Indolent B-cell Non-Hodgkin's Lymphoma (B-NHL)

    Not yet reported Novartis Pharmaceuticals 49 participants Est. completion 2016-12-20 22 sites Stand-alone
    Other conditions: Lymphoma, Non-Hodgkin
    View official trial listing →
  • Completed NCT NCT01296256

    Bendamustine, Cytarabine, Etoposide and Melphalan (BeEAM) as Conditioning for Autologous Stem Cell Transplant (ASCT) in Aggressive Non Hodgkin's Lymphoma (NHL).

    Not yet reported Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea 60 participants Est. completion 2015-11 21 sites Stand-alone
    Other conditions: Bendamustine, Conditioning Therapy, Autologous Stem Cell Transplant, Aggressive Non Hodgkin's Lymphoma
    View official trial listing →
  • Completed NCT NCT01300247

    A Study of Obinutuzumab (GA101; RO5072759) in Combination With Chemotherapy in Participants With Previously Untreated Chronic Lymphocytic Leukemia (CLL) (GALTON)

    Not yet reported Genentech, Inc. 41 participants Est. completion 2015-12 18 sites Stand-alone
    Other conditions: Lymphocytic Leukemia, Chronic
    View official trial listing →
  • Terminated NCT NCT01313611

    BRIEF Bendamustine and Rituximab In Elderly Follicular

    Not yet reported The Lymphoma Academic Research Organisation 62 participants Est. completion 2017-12 117 sites Stand-alone
    Other conditions: Follicular Lymphoma
    View official trial listing →
  • Terminated NCT NCT01315873

    Bortezomib and Bendamustine to Treat Relapsed/Refractory Myeloma

    Not yet reported NYU Langone Health 24 participants Est. completion 2015-09 1 site Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Completed NCT NCT01317901

    A Study of TRU-016 in Combination With Rituximab and Bendamustine in Subjects With Relapsed Indolent Lymphoma

    Not yet reported Aptevo Therapeutics 12 participants Est. completion 2013-06 6 sites Stand-alone
    Other conditions: B-cell Small Lymphocytic Lymphoma Recurrent
    View official trial listing →
  • Completed NCT NCT01326702

    Veliparib, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory Lymphoma, Multiple Myeloma, or Solid Tumors

    Not yet reported, Not yet reported National Cancer Institute (NCI) 43 participants Est. completion 2015-04 1 site Stand-alone
    Obstructive sleep apnea Other conditions: Adult B Acute Lymphoblastic Leukemia, Adult Nasal Type Extranodal NK/T-Cell Lymphoma, Adult Solid Neoplasm, Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-Cell Lymphoma, Chronic Lymphocytic Leukemia, Cutaneous B-Cell Non-Hodgkin Lymphoma, Hepatosplenic T-Cell Lymphoma, Intraocular Lymphoma, Lymphomatous Involvement of Non-Cutaneous Extranodal Site, Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma, Nodal Marginal Zone Lymphoma, Recurrent Adult Acute Lymphoblastic Leukemia, Recurrent Adult Burkitt Lymphoma, Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Adult Diffuse Mixed Cell Lymphoma, Recurrent Adult Diffuse Small Cleaved Cell Lymphoma, Recurrent Adult Grade III Lymphomatoid Granulomatosis, Recurrent Adult Hodgkin Lymphoma, Recurrent Adult Immunoblastic Lymphoma, Recurrent Adult Lymphoblastic Lymphoma, Recurrent Adult T-Cell Leukemia/Lymphoma, Recurrent Cutaneous T-Cell Non-Hodgkin Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Grade 3 Follicular Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Marginal Zone Lymphoma, Recurrent Mycosis Fungoides and Sezary Syndrome, Recurrent Small Lymphocytic Lymphoma, Refractory Chronic Lymphocytic Leukemia, Refractory Hairy Cell Leukemia, Refractory Plasma Cell Myeloma, Small Intestinal Lymphoma, Splenic Marginal Zone Lymphoma, Testicular Lymphoma, Waldenstrom Macroglobulinemia
    View official trial listing →
  • Withdrawn NCT NCT01332617

    Phase II Study of Simvastatin for Relapsed/Refractory Myeloma

    Not yet reported University of Louisville Est. completion 2019-02 Stand-alone
    Other conditions: Myeloma
    View official trial listing →
  • Completed NCT NCT01332968

    A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM)

    Not yet reported Hoffmann-La Roche 1401 participants Est. completion 2021-07-30 183 sites Stand-alone
    Other conditions: Non-Hodgkin's Lymphoma
    View official trial listing →
  • Terminated NCT NCT01352312

    Combination of Pentostatin, Bendamustine and Ofatumumab for Treatment of Chronic Lymphocytic Leukemia and Lymphoma

    Not yet reported Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University 10 participants Est. completion 2018-05-10 1 site Stand-alone
    Other conditions: Chronic Lymphocytic Leukemia, B-Cell Non-Hodgkin's Lymphoma
    View official trial listing →
  • Completed NCT NCT01369849

    Akt Inhibitor MK2206, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

    Not yet reported, Not yet reported National Cancer Institute (NCI) 15 participants Est. completion 2014-02 44 sites Stand-alone
    Other conditions: Chronic Lymphocytic Leukemia, Recurrent Small Lymphocytic Lymphoma, Refractory Chronic Lymphocytic Leukemia
    View official trial listing →
  • Completed NCT NCT01376401

    Bendamustine, Bortezomib (Velcade ®) and Prednisone (BVP) in Patients Newly Diagnosed Multiple Myeloma

    Not yet reported PETHEMA Foundation 60 participants Est. completion 2015-12 14 sites
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Completed NCT NCT01400685

    Lenalidomide Plus Bendamustine and Rituximab for Untreated CLL/SLL

    Not yet reported Massachusetts General Hospital 34 participants Est. completion 2018-01 2 sites
    Other conditions: Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, B Chronic Lymphocytic Leukemia
    View official trial listing →
  • Completed NCT NCT01410513

    Study Combining SAR245409 With Rituximab or Bendamustine Plus Rituximab in Patients With Indolent Lymphoma, Mantle Cell Lymphoma and Chronic Lymphocytic Leukemia

    Not yet reported Sanofi 37 participants Est. completion 2014-05 3 sites Stand-alone
    Other conditions: Indolent Non-Hodgkin Lymphoma, Mantle Cell Lymphoma, Chronic Lymphocytic Leukemia
    View official trial listing →
  • Status unknown NCT NCT01412307

    A Phase 1/2 Study of Lenalidomide in Combination With Bendamustine in Relapsed and Primary Refractory Hodgkin Lymphoma

    Not yet reported, Not yet reported Istituto Nazionale Tumori IRCCS - Fondazione G. Pascale 36 participants Est. completion 2016-07 1 site Stand-alone
    Other conditions: Recurrent Adult Hodgkin Lymphoma
    View official trial listing →
  • Completed NCT NCT01412879

    S1106 Rituximab With Combination Chemotherapy or Bendamustine Hydrochloride Followed by Consolidation Chemotherapy and Stem Cell Transplantation in Older Patients With Previously Untreated Mantle Cell Lymphoma

    Not yet reported SWOG Cancer Research Network 53 participants Est. completion 2021-03 204 sites Stand-alone
    Other conditions: Lymphoma
    View official trial listing →
  • Active, not recruiting NCT NCT01415752

    Rituximab, Bendamustine Hydrochloride, and Bortezomib Followed by Rituximab and Lenalidomide in Treating Older Patients With Previously Untreated Mantle Cell Lymphoma

    Not yet reported Eastern Cooperative Oncology Group 373 participants Est. completion 2031-09 418 sites Stand-alone
    Other conditions: Lymphoma, Mantle Cell Lymphoma
    View official trial listing →
  • Completed NCT NCT01423032

    Bendamustine Versus Fludarabine in Chronic Lymphocytic Leukemia (CLL)

    Not yet reported, Not yet reported WiSP Wissenschaftlicher Service Pharma GmbH 96 participants Est. completion 2009-05 1 site Stand-alone
    Other conditions: Chronic Lymphocytic Leukemia
    View official trial listing →
  • Withdrawn NCT NCT01423539

    A Study of Navitoclax in Addition to Bendamustine and Rituximab in Patients With Relapsed Diffuse Large B-Cell Lymphoma (NAVIGATE)

    Not yet reported Genentech, Inc. Est. completion 2014-02 13 sites Stand-alone
    Other conditions: Diffuse Large B-Cell Lymphoma
    View official trial listing →
  • Completed NCT NCT01429025

    Rituximab, Bendamustine Hydrochloride, and Lenalidomide in Treating Patients With Refractory or Relapsed Indolent Non-Hodgkin Lymphoma

    Not yet reported Alliance for Clinical Trials in Oncology 26 participants Est. completion 2019-07-01 17 sites Stand-alone
    Other conditions: Refractory/Relapsed Indolent Non-Hodgkin Lymphoma
    View official trial listing →
  • Completed NCT NCT01437709

    Ofatumumab With or Without Bendamustine for Patients With Mantle Cell Lymphoma Ineligible for Autologous Stem Cell Transplant

    Not yet reported Memorial Sloan Kettering Cancer Center 30 participants Est. completion 2023-09-12 6 sites Stand-alone
    Other conditions: Mantle Cell Lymphoma
    View official trial listing →
  • Terminated NCT NCT01438177

    Chloroquine in Combination With VELCADE and Cyclophosphamide for Relapsed and Refractory Multiple Myeloma

    Not yet reported NYU Langone Health 11 participants Est. completion 2014-02 1 site
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Completed NCT NCT01456351

    Bendamustine Plus Rituximab Versus Fludarabine Plus Rituximab

    Not yet reported University of Giessen 230 participants Est. completion 2010-12 1 site Stand-alone
    Other conditions: Non-Hodgkin's Lymphoma, Mantle Cell Lymphoma
    View official trial listing →
  • Completed NCT NCT01457144

    Study of Mantle Cell Lymphoma Treatment by RiBVD

    Not yet reported French Innovative Leukemia Organisation 76 participants Est. completion 2016-03 1 site Stand-alone
    Other conditions: Mantle Cell Lymphoma
    View official trial listing →
  • Completed NCT NCT01458366

    Phase I/II Study of Bendamustine in Combination With Ofatumumab, Carboplatin and Etoposide

    Not yet reported, Not yet reported Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University 38 participants Est. completion 2020-07-23 1 site Stand-alone
    Other conditions: Non-Hodgkin's Lymphoma
    View official trial listing →
  • Terminated NCT NCT01465230

    Maintenance Therapy: Lenalidomide Following Bendamustine and Rituximab Induction Therapy for Chronic Lymphocytic Leukemia

    Not yet reported Yale University 2 participants Est. completion 2013-11 1 site Stand-alone
    Other conditions: Chronic Lymphocytic Leukemia
    View official trial listing →
  • Completed NCT NCT01466153

    A Phase 2, Multicenter, Open-label Study of MEDI-551 in Adults With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)

    Not yet reported MedImmune LLC 183 participants Est. completion 2016-01-08 54 sites Stand-alone
    Other conditions: Chronic Lymphocytic Leukemia (CLL)
    View official trial listing →
  • Completed NCT NCT01476787

    Combined Rituximab and Lenalidomide Treatment for Untreated Patients With Follicular Lymphoma

    Not yet reported Celgene 1030 participants Est. completion 2024-04-30 36 sites
    Other conditions: Follicular Lymphoma
    View official trial listing →
  • Active, not recruiting NCT NCT01479842

    Rituxan/Bendamustine/PCI-32765 in Relapsed DLBCL, MCL, or Indolent Non-Hodgkin's Lymphoma

    Not yet reported Kami Maddocks, MD 48 participants Est. completion 2026-12-01 1 site Stand-alone
    Obstructive sleep apnea Other conditions: Nodal Marginal Zone B-cell Lymphoma, Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Grade 3 Follicular Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Marginal Zone Lymphoma, Splenic Marginal Zone Lymphoma, Waldenstrom Macroglobulinemia
    View official trial listing →
  • Terminated NCT NCT01484626

    Bendamustine, Wkly Bortezomib, Lenalidomide and Dexamethasone for Multiple Myeloma

    Not yet reported, Not yet reported Loyola University 3 participants Est. completion 2014-06-18 1 site Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Completed NCT NCT01486797

    NOX-A12 in Combination With Bendamustine and Rituximab in Relapsed Chronic Lymphocytic Leukemia (CLL)

    Not yet reported TME Pharma AG 28 participants Est. completion 2017-04 17 sites
    Other conditions: Chronic Lymphocytic Leukemia
    View official trial listing →
  • Completed NCT NCT01490723

    Zevalin-Containing Nonmyeloablative Conditioning for Stem Cell Transplantation (SCT)

    Not yet reported M.D. Anderson Cancer Center 20 participants Est. completion 2019-04-24 1 site Stand-alone
    Other conditions: Leukemia, Lymphoma
    View official trial listing →
  • Completed NCT NCT01491841

    IIT CTI Bendamustine, Rituximab, Pixantrone in Relapsed/Refractory B Cell Non-Hodgkin's Lymphoma

    Not yet reported Anne Beaven, MD 33 participants Est. completion 2017-02-17 1 site Stand-alone
    Other conditions: Non-Hodgkin's Lymphoma
    View official trial listing →
  • Completed NCT NCT01500083

    Bendamustine Hydrochloride (HCl) in Indolent Non-Hodgkin's Lymphoma That Has Progressed During or Following Treatment With a Rituximab Regimen or Previously Untreated Chronic Lymphocytic Leukemia

    Not yet reported Lundbeck Canada Inc. 90 participants Est. completion 2013-06 16 sites Stand-alone
    Other conditions: Indolent Non-Hodgkin's Lymphoma, Chronic Lymphocytic Leukemia
    View official trial listing →
  • Completed NCT NCT01520922

    Ofatumumab Plus Bendamustine in Frontline and Relapsed Chronic Lymphocytic Leukaemia (CLL)

    Not yet reported Novartis Pharmaceuticals 99 participants Est. completion 2015-11 33 sites Stand-alone
    Other conditions: Chronic Lymphocytic Leukemia (CLL), Leukaemia, Lymphocytic, Chronic
    View official trial listing →
  • Completed NCT NCT01523860

    Brief Chemoimmunotherapy With R+B+M Followed by R in Elderly Patients Advanced Stage Untreated Follicular Lymphoma

    Not yet reported Fondazione Italiana Linfomi - ETS 76 participants Est. completion 2015-01 37 sites Stand-alone
    Other conditions: Follicular Lymphoma
    View official trial listing →
  • Completed NCT NCT01526694

    Phase II Trial Designed to Determine Efficacy and Safety of Bendamustine+Dexamethasone+Thalidomide in R/R MM

    Not yet reported Azienda Ospedaliera di Bolzano 30 participants Est. completion 2017-04-08 19 sites Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Completed NCT NCT01535924

    Gemcitabine and Bendamustine in Patients With Relapsed or Refractory Hodgkin's Lymphoma

    Not yet reported, Not yet reported Beth Christian 26 participants Est. completion 2019-02-20 2 sites Stand-alone
    Other conditions: Adult Lymphocyte Depletion Hodgkin Lymphoma, Adult Lymphocyte Predominant Hodgkin Lymphoma, Adult Mixed Cellularity Hodgkin Lymphoma, Adult Nodular Lymphocyte Predominant Hodgkin Lymphoma, Adult Nodular Sclerosis Hodgkin Lymphoma, Recurrent Adult Hodgkin Lymphoma
    View official trial listing →
  • Completed NCT NCT01558167

    A Safety and Efficacy Trial of a Combination of Bendamustine, Rituximab and Lenalidomide in Patients With Chronic Lymphocytic Leukemia

    Not yet reported, Not yet reported German CLL Study Group 22 participants Est. completion 2015-06 1 site Stand-alone
    Other conditions: Chronic Lymphocytic Leukemia
    View official trial listing →
  • Completed NCT NCT01569295

    Study Evaluating the Efficacy and Safety of Idelalisib in Combination With Bendamustine and Rituximab for Previously Treated Chronic Lymphocytic Leukemia (CLL) (Tugela )

    Not yet reported Gilead Sciences 416 participants Est. completion 2019-06-10 106 sites Stand-alone
    Other conditions: Chronic Lymphocytic Leukemia
    View official trial listing →
  • Status unknown NCT NCT01570049

    Safety and Efficacy Study of Bendamustine to Treat Non-Hodgkin Lymphoma

    Not yet reported Shandong Lanjin Pharmaceuticals Co.,Ltd 100 participants Est. completion 2012-12 2 sites Stand-alone
    Other conditions: Non-Hodgkin Lymphoma by Clinical Course
    View official trial listing →
  • Completed NCT NCT01587040

    Open Label Treatment Extension Study With SAR245408 or SAR245409 as a Monotherapy or as a Combination Regimen

    Not yet reported, Not yet reported Sanofi 61 participants Est. completion 2018-05-23 21 sites Stand-alone
    Other conditions: Neoplasm Malignant
    View official trial listing →
  • Completed NCT NCT01594229

    A Study Evaluating the Safety and Pharmacokinetics of ABT-199 in Combination With Bendamustine/Rituximab (BR) in Subjects With Relapsed or Refractory Non-Hodgkin's Lymphoma

    Not yet reported AbbVie 60 participants Est. completion 2020-07-14 8 sites Stand-alone
    Other conditions: Non-Hodgkin's Lymphoma
    View official trial listing →
  • Completed NCT NCT01596621

    A Study of Bendamustine in the Treatment of Chinese Participants With Indolent Non-Hodgkin Lymphoma Refractory to Rituximab Treatment

    Not yet reported Teva Branded Pharmaceutical Products R&D, Inc. 102 participants Est. completion 2017-04-24 27 sites Stand-alone
    Other conditions: Non-Hodgkin Lymphoma
    View official trial listing →
  • Completed NCT NCT01611090

    A Study of Ibrutinib in Combination With Bendamustine and Rituximab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

    Not yet reported Janssen Research & Development, LLC 578 participants Est. completion 2019-01-23 155 sites Stand-alone
    Other conditions: Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
    View official trial listing →
  • Terminated NCT NCT01612988

    Treatment With Bendamustine, Ofatumumab and MethylPrednisolone in Relapsed B-CLL

    Not yet reported French Innovative Leukemia Organisation 74 participants Est. completion 2018-04 1 site Stand-alone
    Other conditions: B-cell Chronic Lymphocytic Leukemia (B-CLL)
    View official trial listing →
  • Completed NCT NCT01626352

    Study of Bendamustine and Ofatumumab in Elderly Patients With Newly Diagnosed Diffuse Large B-Cell Lymphoma Who Are Poor Candidates for R-CHOP Chemotherapy

    Not yet reported SCRI Development Innovations, LLC 22 participants Est. completion 2017-04 11 sites Stand-alone
    Other conditions: Diffuse Large B-Cell Lymphoma
    View official trial listing →
  • Terminated NCT NCT01644253

    Phase 1b Safety and Efficacy Study of TRU-016

    Not yet reported Aptevo Therapeutics 87 participants Est. completion 2021-04-21 8 sites Stand-alone
    Other conditions: Chronic Lymphocytic Leukemia, Peripheral T-cell Lymphoma
    View official trial listing →
  • Withdrawn NCT NCT01649622

    Bendamustine in Acute Lymphoblastic Leukemia/Lymphoma (ALL)

    Not yet reported M.D. Anderson Cancer Center Stand-alone
    Other conditions: Leukemia, Lymphoma
    View official trial listing →
  • Completed NCT NCT01650701

    A Phase 3 Open Label Randomized Study to Compare the Efficacy and Safety of Rituximab Plus Lenalidomide (CC-5013) Versus Rituximab Plus Chemotherapy Followed by Rituximab in Subjects With Previously Untreated Follicular Lymphoma

    Not yet reported The Lymphoma Academic Research Organisation 1030 participants Est. completion 2024-04-30 35 sites
    Other conditions: Follicular Lymphoma
    View official trial listing →
  • Completed NCT NCT01657331

    Brentuximab Vedotin and Bendamustine for the Treatment of Hodgkin Lymphoma and Anaplastic Large Cell Lymphoma (ALCL)

    Not yet reported, Not yet reported Columbia University 65 participants Est. completion 2018-06 3 sites Stand-alone
    Other conditions: Hodgkin Lymphoma, Anaplastic Large Cell Lymphoma
    View official trial listing →
  • Status unknown NCT NCT01657955

    Bendamustine Hydrochloride Injection for Previously Untreated Chronic Lymphocytic Leukemia

    Not yet reported Shandong Lanjin Pharmaceuticals Co.,Ltd 96 participants Est. completion 2013-12 1 site Stand-alone
    Other conditions: Chronic Lymphocytic Leukemia, Leukemia, Neoplasms
    View official trial listing →
  • Active, not recruiting NCT NCT01661881

    Rituximab/Bendamustine + Rituximab/Cytarabine for Mantle Cell Lymphoma

    Not yet reported Christine Ryan 23 participants Est. completion 2030-04 1 site Stand-alone
    Other conditions: Mantle Cell Lymphoma
    View official trial listing →
  • Completed NCT NCT01662050

    Phase II Study of Age-Adjusted Rituximab, Bendamustine, Cytarabine as Induction Therapy in Older Patients With MCL

    Not yet reported Fondazione Italiana Linfomi - ETS 57 participants Est. completion 2017-09-11 56 sites Stand-alone
    Other conditions: Mantle Cell Lymphoma
    View official trial listing →
  • Completed NCT NCT01664910

    CMC-544 and Allogeneic Transplantation for CD22 Positive-Lymphoid Malignancies

    Not yet reported, Not yet reported M.D. Anderson Cancer Center 27 participants Est. completion 2023-06-28 1 site Stand-alone
    Other conditions: Hematopoietic and Lymphoid Cell Neoplasm
    View official trial listing →
  • Completed NCT NCT01671904

    A Study of Venetoclax in Combination With Bendamustine + Rituximab or Bendamustine + Obinutuzumab in Participants With Relapsed/Refractory or Previously Untreated Chronic Lymphocytic Leukemia (CLL)

    Not yet reported Genentech, Inc. 84 participants Est. completion 2020-08-11 12 sites Stand-alone
    Other conditions: Chronic Lymphocytic Leukemia
    View official trial listing →
  • Status unknown NCT NCT01678430

    A Trial Looking at Ofatumumab for People With Chronic Lymphocytic Leukaemia Who Cannot Have More Intensive Treatment

    Not yet reported University of Liverpool 670 participants Est. completion 2017-12 28 sites Stand-alone
    Other conditions: Chronic Lymphocytic Leukaemia
    View official trial listing →
  • Completed NCT NCT01686321

    Rituximab and Bendamustine in Very Elderly Patients or Elderly Medically Non Fit Patients With Aggressive B-cell Lymphoma

    Not yet reported University of Göttingen 68 participants Est. completion 2018-08-08 1 site Stand-alone
    Other conditions: Aggressive Lymphoma
    View official trial listing →
  • Status unknown NCT NCT01686386

    Study of Bendamustine, Lenalidomide and Low-dose Dexamethasone, for the Treatment of Patients With Relapsed Myeloma

    Not yet reported, Not yet reported Gruppo Italiano Studio Linfomi 60 participants Est. completion 2013-10 1 site Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Completed NCT NCT01691807

    Drug-drug Interaction Study of Ofatumumab With Bendamustine in Subjects With Indolent B-cell Non-Hodgkin's Lymphoma

    Not yet reported Novartis Pharmaceuticals 30 participants Est. completion 2015-12 5 sites Stand-alone
    Other conditions: Cancer
    View official trial listing →
  • Completed NCT NCT01701076

    Bendamustine, Lenalidomide (Revlimid®) and Dexamethasone (BRd) as 2nd-line Therapy for Patients With Relapsed or Refractory Multiple Myeloma

    Not yet reported Cantonal Hospital of St. Gallen 50 participants Est. completion 2016-02 1 site Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Completed NCT NCT01716806

    A Study of Brentuximab Vedotin With Hodgkin Lymphoma (HL) and CD30-expressing Peripheral T-cell Lymphoma (PTCL)

    Not yet reported Seagen Inc. 131 participants Est. completion 2023-09-12 54 sites Stand-alone
    Other conditions: Hodgkin Disease, Peripheral T Cell Lymphoma
    View official trial listing →
  • Completed NCT NCT01724021

    A Study of Participant Preference With Subcutaneous Versus Intravenous MabThera/Rituxan in Participants With CD20+ Diffuse Large B-Cell Lymphoma or CD20+ Follicular Non-Hodgkin's Lymphoma Grades 1, 2 or 3a

    Not yet reported Hoffmann-La Roche 743 participants Est. completion 2015-01 246 sites Stand-alone
    Other conditions: Diffuse Large B-Cell Lymphoma, Non-Hodgkin's Lymphoma
    View official trial listing →
  • Terminated NCT NCT01732926

    Efficacy and Safety of Idelalisib (GS-1101) in Combination With Bendamustine and Rituximab for Previously Treated Indolent Non-Hodgkin Lymphomas

    Not yet reported Gilead Sciences 475 participants Est. completion 2016-05-17 144 sites Stand-alone
    Other conditions: Indolent Non-Hodgkin's Lymphomas
    View official trial listing →
  • Completed NCT NCT01737177

    Bendamustine/Lenalidomide/Rituximab: Combination as a Second-Line Therapy for 1st Relapsed-Refractory MCL

    Not yet reported Fondazione Italiana Linfomi - ETS 42 participants Est. completion 2017-02-02 43 sites Stand-alone
    Other conditions: Mantle Cell Lymphoma
    View official trial listing →
  • Withdrawn NCT NCT01739491

    A Study of Safety and Effectiveness of Bendamustine Hydrochloride in Adult Filipino Patients With Chronic Lymphocytic Leukemia

    Janssen Pharmaceutica Est. completion 2016-11
    Other conditions: Chronic Lymphocytic Leukemia
    View official trial listing →
  • Status unknown NCT NCT01754402

    Bendamustine + Pomalidomide + Dex in R/R Multiple Myeloma

    Not yet reported, Not yet reported Cristina Gasparetto 56 participants Est. completion 2025-01-01 1 site Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Completed NCT NCT01754857

    Bendamustine and Rituximab Induction Therapy and Maintenance Rituximab and Lenalidomide in Previously Untreated CLL/SLL

    Not yet reported University of Wisconsin, Madison 36 participants Est. completion 2022-06-30 1 site Stand-alone
    Other conditions: Lymphoid Leukemia, Small Lymphocytic Lymphoma, Lymphoma, Non-Hodgkin
    View official trial listing →
  • Withdrawn NCT NCT01754870

    Phase II Study of Bendamustine and Rituximab Induction Chemoimmunotherapy Followed by Maintenance Rituximab (Rituxan®) and Lenalidomide (Revlimid®) in Relapsed and Refractory Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL)

    Not yet reported University of Wisconsin, Madison Est. completion 2014-08 Stand-alone
    Other conditions: Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL)
    View official trial listing →
  • Completed NCT NCT01776840

    A Study of the Bruton's Tyrosine Kinase Inhibitor Ibrutinib Given in Combination With Bendamustine and Rituximab in Patients With Newly Diagnosed Mantle Cell Lymphoma

    Not yet reported Janssen Research & Development, LLC 523 participants Est. completion 2024-06-24 201 sites Stand-alone
    Other conditions: Mantle Cell Lymphoma
    View official trial listing →
  • Completed NCT NCT01831505

    Feasibility of Assessing Lymphoma Response to Precise Local Injection of Candidate Chemotherapy Agents

    Not yet reported Presage Biosciences 4 participants Est. completion 2013-07 1 site Stand-alone
    Other conditions: Lymphoma
    View official trial listing →
  • Completed NCT NCT01832597

    Efficacy and Safety Study of Bendamustine With or Without Rituximab in Chronic Lymphoproliferative Disorders

    Gruppo Italiano Studio Linfomi 109 participants Est. completion 2011-01 3 sites
    Other conditions: Chronic Lymphocytic Leukaemia
    View official trial listing →
  • Completed NCT NCT01832922

    BR in Patients With CLL With Comorbidities and/or Renal Dysfunction

    Not yet reported Dartmouth-Hitchcock Medical Center 8 participants Est. completion 2016-11-28 2 sites Stand-alone
    Other conditions: Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
    View official trial listing →
  • Completed NCT NCT01871675

    Study of IPI-145 in Combination With Rituximab or Bendamustine/Rituximab in Hematologic Malignancies

    Not yet reported SCRI Development Innovations, LLC 48 participants Est. completion 2016-06 4 sites Stand-alone
    Other conditions: Lymphoma, Chronic Lymphocytic Leukemia, Non-Hodgkin Lymphoma, T-cell Lymphoma
    View official trial listing →
  • Completed NCT NCT01874054

    Study of Brentuximab Vedotin Combined With Bendamustine in Patients With Hodgkin Lymphoma

    Not yet reported, Not yet reported Seagen Inc. 55 participants Est. completion 2018-02-20 13 sites Stand-alone
    Other conditions: Hodgkin Disease
    View official trial listing →
  • Status unknown NCT NCT01884441

    Bendamustine, Gemcitabine and Vinorelbine (BeGEV) as Induction Therapy in Relapsed/Refractory Hodgkin's Lymphoma Patients

    Not yet reported Armando Santoro, MD 59 participants Est. completion 2016-07 1 site Stand-alone
    Other conditions: Hodgkin's Lymphoma
    View official trial listing →
  • Active, not recruiting NCT NCT01886872

    Rituximab and Bendamustine Hydrochloride, Rituximab and Ibrutinib, or Ibrutinib Alone in Treating Older Patients With Previously Untreated Chronic Lymphocytic Leukemia

    Not yet reported National Cancer Institute (NCI) 547 participants Est. completion 2027-06-24 937 sites
    Other conditions: Stage I Chronic Lymphocytic Leukemia, Stage II Chronic Lymphocytic Leukemia, Stage III Chronic Lymphocytic Leukemia, Stage IV Chronic Lymphocytic Leukemia
    View official trial listing →
  • Completed NCT NCT01889069

    A Study to Evaluate Safety, Efficacy and Pharmacokinetics of Rituximab (MabThera/Rituxan) in Participants With Diffuse Large B Cell Lymphoma (DLBCL) or Follicular Lymphoma (FL)

    Not yet reported Hoffmann-La Roche 159 participants Est. completion 2019-05-28 39 sites Stand-alone
    Other conditions: Lymphoma
    View official trial listing →
  • Completed NCT NCT01891227

    Capecitabine + Bendamustine in Women With Pretreated Locally Advanced or Metastatic Her2-negative Breast Cancer

    Not yet reported Arbeitsgemeinschaft medikamentoese Tumortherapie 40 participants Est. completion 2018-03-15 8 sites Stand-alone
    Other conditions: Breast Cancer
    View official trial listing →
  • Completed NCT NCT01900509

    Bendamustine Hydrochloride, Clofarabine, and Etoposide in Treating Younger Patients With Relapsed or Refractory Hematologic Malignancies

    Not yet reported St. Jude Children's Research Hospital 16 participants Est. completion 2016-05 1 site Stand-alone
    Other conditions: Hodgkin Lymphoma, Non-Hodgkin Lymphoma, Acute Leukemia
    View official trial listing →
  • Completed NCT NCT01905943

    A Safety and Efficacy Study of Obinutuzumab Alone or in Combination With Chemotherapy in Participants With Chronic Lymphocytic Leukemia

    Not yet reported Hoffmann-La Roche 979 participants Est. completion 2018-10-08 174 sites Stand-alone
    Other conditions: Chronic Lymphocytic Leukemia
    View official trial listing →
  • Completed NCT NCT01929265

    A Phase II Study for Patients With Indolent Non-follicular Non-Hodgkin's Lymphoma

    Not yet reported Fondazione Italiana Linfomi - ETS 73 participants Est. completion 2015-05 25 sites Stand-alone
    Other conditions: Indolent Non-follicular, Non-Hodgkin's Lymphoma
    View official trial listing →
  • Completed NCT NCT01974440

    A Study of PCI-32765 (Ibrutinib) in Combination With Either Bendamustine and Rituximab or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Participants With Previously Treated Indolent Non-Hodgkin Lymphoma

    Not yet reported Janssen Research & Development, LLC 403 participants Est. completion 2023-06-21 135 sites Stand-alone
    Other conditions: Lymphoma
    View official trial listing →
  • Terminated NCT NCT01980888

    Efficacy and Safety of Idelalisib in Combination With Bendamustine and Rituximab in Adults With Previously Untreated Chronic Lymphocytic Leukemia

    Not yet reported Gilead Sciences 311 participants Est. completion 2016-06-16 91 sites Stand-alone
    Other conditions: Chronic Lymphocytic Leukemia
    View official trial listing →
  • Status unknown NCT NCT01990144

    Rituximab Plus Bendamustine as Front Line Treatment in Frail Elderly (>70 Years) Patients With DLBCL: a Phase II Multicenter Study of the FIL

    Not yet reported Fondazione Italiana Linfomi - ETS 49 participants Est. completion 2016-02 52 sites Stand-alone
    Other conditions: Diffuse Large B-cell Lymphoma
    View official trial listing →
  • Terminated NCT NCT02002598

    Carfilzomib With Bendamustine and Dexamethasone in Multiple Myeloma

    Not yet reported, Not yet reported Suzanne Lentzsch, MD 23 participants Est. completion 2023-07-01 1 site Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Completed NCT NCT02005471

    A Study to Evaluate the Benefit of Venetoclax Plus Rituximab Compared With Bendamustine Plus Rituximab in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)

    Not yet reported Hoffmann-La Roche 389 participants Est. completion 2022-08-03 111 sites Stand-alone
    Other conditions: Chronic Lymphocytic Leukemia
    View official trial listing →
  • Completed NCT NCT02006485

    Ublituximab in Combination With TGR-1202 +/- Ibrutinib or Bendamustine in Patients With B-cell Malignancies

    Not yet reported TG Therapeutics, Inc. 160 participants Est. completion 2019-10 6 sites Stand-alone
    Other conditions: Chronic Lymphocytic Leukemia, Non-Hodgkin's Lymphoma
    View official trial listing →
  • Terminated NCT NCT02008006

    BENdamustine at Elevated Dose for Relapsed Follicular Lymphoma in Intensification Therapy and Transplantation (BENEFIT)

    Not yet reported Centre Leon Berard 21 participants Est. completion 2018-07-12 13 sites Stand-alone
    Other conditions: Follicular Lymphoma
    View official trial listing →
  • Completed NCT NCT02056756

    Carfilzomib In Combination With Bendamustine And Dexamethasone In Refractory Or Relapsed Multiple Myeloma

    Not yet reported, Not yet reported Stichting European Myeloma Network 63 participants Est. completion 2023-01-30 3 sites
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Completed NCT NCT02059239

    Bendamustine Bridge to Autologous or Allogeneic Transplant for Relapsed/Refractory Lymphoma

    Not yet reported, Not yet reported Weill Medical College of Cornell University 34 participants Est. completion 2020-06-15 1 site Stand-alone
    Other conditions: Hodgkin's Lymphoma, Non-Hodgkin's Lymphoma
    View official trial listing →
  • Completed NCT NCT02063685

    Study to Evaluate the Efficacy of Response-adapted Strategy in Follicular Lymphoma

    Not yet reported Fondazione Italiana Linfomi - ETS 807 participants Est. completion 2021-12 48 sites Stand-alone
    Other conditions: Follicular Non-Hodgkin's Lymphoma
    View official trial listing →
  • Completed NCT NCT02071225

    A Study Evaluating the Efficacy of Obinutuzumab and Bendamustine Treatment in Participants With Refractory or Relapsed Chronic Lymphocytic Leukemia

    Not yet reported Hoffmann-La Roche 72 participants Est. completion 2018-11-19 21 sites Stand-alone
    Other conditions: Chronic Lymphocytic Leukemia
    View official trial listing →
  • Completed NCT NCT02072967

    Ribomustin in the Second Line Therapy of Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma

    Astellas Pharma Europe B.V. 97 participants Est. completion 2015-10 35 sites
    Other conditions: Lymphoma, Non-Hodgkin
    View official trial listing →
  • Completed NCT NCT02095834

    Carfilzomib, Bendamustine Hydrochloride, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma

    Not yet reported M.D. Anderson Cancer Center 18 participants Est. completion 2021-01-07 1 site Stand-alone
    Other conditions: Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma
    View official trial listing →
  • Completed NCT NCT02110394

    Ribomustin in the First Line Therapy of Chronic Lymphocytic Leukemia

    Astellas Pharma Europe B.V. 190 participants Est. completion 2015-08 34 sites
    Other conditions: Chronic Lymphocytic Leukemia
    View official trial listing →
  • Completed NCT NCT02130869

    A Pilot Study of Immunotherapy Including Haploidentical NK Cell Infusion Following CD133+ Positively-Selected Autologous Hematopoietic Stem Cells in Children With High Risk Solid Tumors or Lymphomas

    Not yet reported St. Jude Children's Research Hospital 8 participants Est. completion 2017-12-20 1 site Stand-alone
    Other conditions: Neuroblastoma, Lymphoma, High-risk Tumor
    View official trial listing →
  • Status unknown NCT NCT02134262

    Gene Therapy for B-Cell Non-Hodgkin Lymphoma Using CD19 CAR Gene Transduced T Lymphocytes

    Not yet reported, Not yet reported Jichi Medical University 18 participants Est. completion 2017-03 1 site Stand-alone
    Other conditions: Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma
    View official trial listing →
  • Completed NCT NCT02148913

    Phase I: Melphalan, Bendamustine and Carfilzomib for Autologous Transplant in Multiple Myeloma

    Not yet reported Corewell Health West 18 participants Est. completion 2018-12 1 site
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Active, not recruiting NCT NCT02153580

    Cellular Immunotherapy Following Chemotherapy in Treating Patients With Recurrent Non-Hodgkin Lymphomas, Chronic Lymphocytic Leukemia, or B-Cell Prolymphocytic Leukemia

    Not yet reported City of Hope Medical Center 37 participants Est. completion 2027-08-11 1 site Stand-alone
    Other conditions: B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Classic Hodgkin Lymphoma, B-Cell Prolymphocytic Leukemia, High Grade B-Cell Lymphoma, Not Otherwise Specified, Post-Transplant Lymphoproliferative Disorder, Recurrent Adult Burkitt Lymphoma, Recurrent Chronic Lymphocytic Leukemia, Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Follicular Lymphoma, Recurrent Hairy Cell Leukemia, Recurrent Lymphoplasmacytic Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Marginal Zone Lymphoma, Recurrent Small Lymphocytic Lymphoma
    View official trial listing →
  • Completed NCT NCT02162888

    A Phase I, Bioequivalence Study to Evaluate Two Formulations of Bendamustine (BDM) Hydrochloride (HCl) Administered to Cancer Patients

    Not yet reported Eagle Pharmaceuticals, Inc. 81 participants Est. completion 2014-11 10 sites
    Other conditions: Cancer Which Has Either Progressed or Relapsed After Standard Therapy, or for Which no Curative or Standard Therapy is Appropriate
    View official trial listing →
  • Completed NCT NCT02168140

    CPI-613 and Bendamustine Hydrochloride in Treating Patients With Relapsed or Refractory T-Cell Non-Hodgkin Lymphoma or Hodgkin Lymphoma

    Not yet reported Wake Forest University Health Sciences 16 participants Est. completion 2022-09-15 2 sites Stand-alone
    Other conditions: Adult Lymphocyte Depletion Hodgkin Lymphoma, Adult Lymphocyte Predominant Hodgkin Lymphoma, Adult Mixed Cellularity Hodgkin Lymphoma, Adult Nasal Type Extranodal NK/T-cell Lymphoma, Adult Nodular Sclerosis Hodgkin Lymphoma, Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma, Hepatosplenic T-cell Lymphoma, Noncutaneous Extranodal Lymphoma, Peripheral T-cell Lymphoma, Recurrent Adult Acute Lymphoblastic Leukemia, Recurrent Adult Hodgkin Lymphoma, Recurrent Adult T-cell Leukemia/Lymphoma, Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma, Recurrent Mycosis Fungoides/Sezary Syndrome, T-cell Adult Acute Lymphoblastic Leukemia, T-cell Large Granular Lymphocyte Leukemia
    View official trial listing →
  • Terminated NCT NCT02168907

    CPI-613, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

    Not yet reported Wake Forest University Health Sciences 1 participants Est. completion 2015-02 1 site Stand-alone
    Obstructive sleep apnea Other conditions: B-cell Adult Acute Lymphoblastic Leukemia, B-cell Chronic Lymphocytic Leukemia, Cutaneous B-cell Non-Hodgkin Lymphoma, Intraocular Lymphoma, Nodal Marginal Zone B-cell Lymphoma, Recurrent Adult Acute Lymphoblastic Leukemia, Recurrent Adult Burkitt Lymphoma, Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Adult Diffuse Mixed Cell Lymphoma, Recurrent Adult Diffuse Small Cleaved Cell Lymphoma, Recurrent Adult Grade III Lymphomatoid Granulomatosis, Recurrent Adult Immunoblastic Large Cell Lymphoma, Recurrent Adult Lymphoblastic Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Grade 3 Follicular Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Marginal Zone Lymphoma, Recurrent Mycosis Fungoides/Sezary Syndrome, Recurrent Small Lymphocytic Lymphoma, Refractory Chronic Lymphocytic Leukemia, Refractory Hairy Cell Leukemia, Small Intestine Lymphoma, Splenic Marginal Zone Lymphoma, Testicular Lymphoma, Waldenström Macroglobulinemia
    View official trial listing →
  • Completed NCT NCT02187133

    Carfilzomib With Bendamustine and Rituximab in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma

    Not yet reported University of California, San Francisco 10 participants Est. completion 2021-03-31 3 sites Stand-alone
    Other conditions: Lymphoma, Non-Hodgkin, Lymphoma
    View official trial listing →
  • Completed NCT NCT02187861

    A Study Evaluating the Safety and Efficacy of Venetoclax (GDC-0199) Plus Bendamustine + Rituximab (BR) in Comparison With BR or Venetoclax Plus Rituximab in Participants With Relapsed and Refractory Follicular Non-Hodgkin's Lymphoma (fNHL)

    Not yet reported Hoffmann-La Roche 163 participants Est. completion 2018-03-16 71 sites Stand-alone
    Other conditions: Follicular Lymphoma
    View official trial listing →
  • Withdrawn NCT NCT02194374

    Autologous ROR1R-CAR-T Cells for Chronic Lymphocytic Leukemia (CLL)

    Not yet reported M.D. Anderson Cancer Center Est. completion 2017-06 Stand-alone
    Other conditions: Leukemia
    View official trial listing →
  • Completed NCT NCT02224729

    Bendamustine Hydrochloride, Bortezomib, and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma

    Not yet reported Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University 24 participants Est. completion 2018-11-17 1 site Stand-alone
    Other conditions: Stage I Multiple Myeloma, Stage II Multiple Myeloma, Stage III Multiple Myeloma
    View official trial listing →
  • Completed NCT NCT02237261

    Bendamustine, Prednisone and Velcade® for First-line Treatment of Patients With Symptomatic Multiple Myeloma

    Not yet reported University Hospital Heidelberg 46 participants Est. completion 2018-10 15 sites Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Completed NCT NCT02240719

    Everolimus and Bendamustine Hydrochloride in Treating Patients With Relapsed or Refractory Hematologic Cancer

    Not yet reported University of California, Davis 20 participants Est. completion 2018-04-09 1 site Stand-alone
    Other conditions: Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Adult Hodgkin Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Grade 3 Follicular Lymphoma, Recurrent Mantle Cell Lymphoma, Refractory Chronic Lymphocytic Leukemia, Multiple Myeloma
    View official trial listing →
  • Completed NCT NCT02257242

    Vincristine Sulfate Liposome Injection (Marqibo®), Bendamustine and Rituximab-Phase I Trial in Indolent B-cell Lymphoma

    Not yet reported Brown University 11 participants Est. completion 2020-11-18 1 site Stand-alone
    Other conditions: Lymphoma, Non-Hodgkin, Lymphoma, Follicular, Lymphoma, Mantle-Cell, Lymphoma, Small-Cell, Waldenstrom Macroglobulinemia, Lymphoma, B-Cell, Marginal Zone
    View official trial listing →
  • Completed NCT NCT02257567

    A Study of Polatuzumab Vedotin (DCDS4501A) in Combination With Rituximab or Obinutuzumab Plus Bendamustine in Participants With Relapsed or Refractory Follicular or Diffuse Large B-Cell Lymphoma

    Not yet reported, Not yet reported Hoffmann-La Roche 331 participants Est. completion 2021-10-21 62 sites Stand-alone
    Other conditions: Lymphoma
    View official trial listing →
  • Completed NCT NCT02278796

    A Trial Comparing the Two High-dose Chemotherapies BeEAM and BEAM Given Before Autologous Stem Cell Transplantation (ASCT) in Lymphoma Patients (BEB-trial)

    Not yet reported Insel Gruppe AG, University Hospital Bern 108 participants Est. completion 2020-11 4 sites Stand-alone
    Other conditions: Lymphoma, Large B-Cell, Diffuse, Lymphoma, Follicular, Lymphoma, Mantle-Cell
    View official trial listing →
  • Withdrawn NCT NCT02315157

    Bendamustine Hydrochloride in Treating Patients With Previously Treated Multiple Myeloma

    Not yet reported Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University Est. completion 2018-11 1 site Stand-alone
    Other conditions: Multiple Myeloma, Plasma Cell Leukemia
    View official trial listing →
  • Status unknown NCT NCT02320383

    CLLR3: Bendamustine + GA101 (BG) in Relapsed or Refractory CLL Followed by GA101 Maintenance for Responding Patients

    Not yet reported Munich Municipal Hospital 27 participants Est. completion 2022-09 1 site Stand-alone
    Other conditions: Chronic Lymphocytic Leucemia
    View official trial listing →
  • Completed NCT NCT02320487

    A Study of Obinutuzumab + Bendamustine (BG) in Participants With Previously Untreated Chronic Lymphocytic Leukemia (CLL)

    Not yet reported Genentech, Inc. 102 participants Est. completion 2019-02-06 26 sites Stand-alone
    Other conditions: Chronic Lymphocytic Leukemia
    View official trial listing →
  • Completed NCT NCT02345863

    Sequential Regimen of Bendamustin [B] Followed by GA101 and Ibrutinib [I] in CLL Patients

    Not yet reported German CLL Study Group 66 participants Est. completion 2019-03-29 1 site Stand-alone
    Other conditions: Chronic Lymphocytic Leucemia
    View official trial listing →
  • Completed NCT NCT02348216

    Study Evaluating the Safety and Efficacy of KTE-C19 in Adult Participants With Refractory Aggressive Non-Hodgkin Lymphoma

    Not yet reported, Not yet reported Kite, A Gilead Company 307 participants Est. completion 2023-07-27 36 sites Stand-alone
    Other conditions: Refractory Diffuse Large B Cell Lymphoma (DLBCL), Relapsed Diffuse Large B-Cell Lymphoma, Transformed Follicular Lymphoma (TFL), Primary Mediastinal B-cell Lymphoma (PMBCL), High Grade B-cell Lymphoma (HGBCL)
    View official trial listing →
  • Completed NCT NCT02371148

    Fase II Study With BRB for Non-Hodgkin Lymphoplasmacytic Lymphoma/Waldenstrom Macroglobulinemia's

    Not yet reported Fondazione Italiana Linfomi - ETS 38 participants Est. completion 2020-07-22 23 sites Stand-alone
    Other conditions: Waldenstrom's Macroglobulinemia
    View official trial listing →
  • Completed NCT NCT02381899

    Observational Study in CLL Patients Receiving BR

    Czech CLL Study Group 83 participants Est. completion 2018-12 5 sites
    Other conditions: Chronic Lymphocytic Leukemia
    View official trial listing →
  • Completed NCT NCT02401503

    Sequential Regimen of Bendamustine-Debulking Followed by ABT-199 and GA101-Induction and -Maintenance in CLL (CLL2-BAG)

    Not yet reported German CLL Study Group 66 participants Est. completion 2024-12-17 1 site Stand-alone
    Other conditions: Chronic Lymphocytic Leucemia
    View official trial listing →
  • Active, not recruiting NCT NCT02414022

    Economic Analysis of Alliance A041202 CLL Study

    Canadian Cancer Trials Group 55 participants Est. completion 2026-12-31 15 sites
    Other conditions: Chronic Lymphocytic Leukemia
    View official trial listing →
  • Completed NCT NCT02414568

    Bendamustine Study in Classical Hodgkin Lymphoma Patients Over 60 Treated by Prednisone, Vinblastine and Doxorubicin

    Not yet reported The Lymphoma Academic Research Organisation 90 participants Est. completion 2020-11-10 40 sites Stand-alone
    Other conditions: Classical Hodgkin Lymphoma
    View official trial listing →
  • Completed NCT NCT02416206

    High Dose Chemotherapy Using BeEAM for Autologous Transplant in Multiple Myeloma

    Not yet reported Northside Hospital, Inc. 65 participants Est. completion 2021-04-21 1 site
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Terminated NCT NCT02420210

    Bendamustine, Obinutuzumab, and Dexamethasone in Older Patients With Diffuse Large B-cell Lymphoma

    Not yet reported University of Chicago 2 participants Est. completion 2016-08 1 site Stand-alone
    Other conditions: Diffuse Large B-Cell Lymphoma
    View official trial listing →
  • Status unknown NCT NCT02423837

    Bendamustine in Combination With Rituximab as a First-line Therapy Followed by Maintenance Therapy With Rituximab in Patients With Follicular Lymphoma

    Not yet reported National Research Center for Hematology, Russia 200 participants Est. completion 2021-04 1 site
    Other conditions: Follicular Lymphoma
    View official trial listing →
  • Completed NCT NCT02424045

    Bendamustine, Carboplatin and Dexamethasone (BCD) for Refractory or Relapsed Peripheral T-cell Lymphoma

    Not yet reported Samsung Medical Center 30 participants Est. completion 2017-09
    Other conditions: T-cell Lymphoma
    View official trial listing →
  • Completed NCT NCT02424851

    Optimising Renal Outcome in Myeloma Renal Failure

    Not yet reported Oxford University Hospitals NHS Trust 31 participants Est. completion 2020-04-20 9 sites
    Chronic kidney disease Other conditions: Multiple Myeloma
    View official trial listing →
  • Completed NCT NCT02433795

    Bendamustine Plus Rituximab (BR) for Relapsed or Progressive Marginal Zone B-cell Lymphoma (MZBCL)

    Not yet reported Seoul National University Hospital 27 participants Est. completion 2019-10 11 sites Stand-alone
    Other conditions: Marginal Zone B-cell Lymphoma
    View official trial listing →
  • Completed NCT NCT02434484

    Symbenda Post-Marketing Surveillance (PMS)

    Eisai Korea Inc. 84 participants Est. completion 2020-03-20 9 sites
    Other conditions: Lymphoma, Non-Hodgkin, Lymphocytic Leukemia, Multiple Myeloma
    View official trial listing →
  • Completed NCT NCT02445131

    Sequential Regimen of Bendamustine-Debulking Followed by CAL-101 and GA101-Induction and -Maintenance in CLL (CLL2-BCG)

    Not yet reported German CLL Study Group 48 participants Est. completion 2022-03-09 1 site Stand-alone
    Other conditions: Chronic Lymphocytic Leucemia
    View official trial listing →
  • Completed NCT NCT02467946

    Hodgkin Lymphoma Treatment With Adcetris and Levact in the Old Patient

    Not yet reported, Not yet reported Centre Antoine Lacassagne 60 participants Est. completion 2022-04-06 1 site
    Other conditions: Clinical Efficacy, Safety
    View official trial listing →
  • Completed NCT NCT02477215

    Study of Bendamustine and IXAZOMIB (MLN9708) Plus Dexamethasone in Relapsed/Refractory Multiple Myeloma

    Not yet reported, Not yet reported Parameswaran Hari 38 participants Est. completion 2020-09-17 1 site Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Completed NCT NCT02491398

    Efficacy and Safety of Bendamustine Plus Rituximab in Chronic Lympocytic Leukemia

    Gruppo Italiano Malattie EMatologiche dell'Adulto 494 participants Est. completion 2017-01 41 sites
    Other conditions: Chronic Lymphocytic Leukemia
    View official trial listing →
  • Terminated NCT NCT02499627

    Bendamustine Plus Brentuximab Vedotin in HL and CD30+ PTCL in First Salvage Setting

    Not yet reported Fondazione Italiana Linfomi - ETS 43 participants Est. completion 2020-06-30 5 sites Stand-alone
    Other conditions: Lymphatic Diseases
    View official trial listing →
  • Withdrawn NCT NCT02576275

    A Study of Duvelisib in Combination With Rituximab and Bendamustine vs Placebo in Combination With Rituximab and Bendamustine in Subjects With Previously-Treated Indolent Non-Hodgkin Lymphoma (BRAVURA)

    Not yet reported SecuraBio Est. completion 2016-11 7 sites Stand-alone
    Other conditions: Indolent Non-Hodgkin's Lymphoma, Follicular Lymphoma, Small Lymphocytic Lymphoma, Marginal Zone Lymphoma
    View official trial listing →
  • Terminated NCT NCT02594163

    Study of Rituximab and Bendamustine With or Without Brentuximab Vedotin for CD30 Positive Diffuse Large B-cell Lymphoma

    Not yet reported Seagen Inc. 25 participants Est. completion 2017-09 50 sites Stand-alone
    Other conditions: Diffuse Large B-cell Lymphoma Refractory, Follicular B-cell Non-Hodgkin's Lymphoma
    View official trial listing →
  • Completed NCT NCT02596971

    A Study of Atezolizumab in Combination With Either Obinutuzumab Plus Bendamustine or Obinutuzumab Plus (+) Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) in Participants With Follicular Lymphoma (FL) or Rituximab + CHOP in Participants With Diffuse Large B-Cell Lymphoma (DLBCL)

    Not yet reported, Not yet reported Hoffmann-La Roche 91 participants Est. completion 2020-05-08 21 sites Stand-alone
    Other conditions: Diffuse Large B-Cell Lymphoma, Lymphoma Follicular
    View official trial listing →
  • Withdrawn NCT NCT02623920

    Brentuximab Vedotin, Bendamustine, and Rituximab in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma

    Not yet reported University of Arizona Est. completion 2017-05-17 1 site Stand-alone
    Other conditions: Diffuse Large B Cell Lymphoma, Mediastinal Large B-cell Lymphoma, Grey Zone Lymphoma, High Grade B Cell Lymphoma, Follicular Lymphoma, Marginal Zone Lymphoma, Small Lymphocytic Lymphoma
    View official trial listing →
  • Terminated NCT NCT02626455

    Study of Copanlisib in Combination With Standard Immunochemotherapy in Relapsed Indolent Non-Hodgkin's Lymphoma (iNHL)

    Not yet reported Bayer 551 participants Est. completion 2023-11-10 201 sites Stand-alone
    Other conditions: Lymphoma, Non-Hodgkin
    View official trial listing →
  • Status unknown NCT NCT02678299

    Phase 1/2 Study of the Combination of Pixantrone, Etoposide, Bendamustine and, in CD20 Positive Tumors, Rituximab in Patients With Relapsed Aggressive Non-Hodgkin Lymphomas of B- or T-cell Phenotype - the P[R]EBEN Study

    Not yet reported, Not yet reported University of Aarhus 60 participants Est. completion 2025-12 18 sites
    Other conditions: Malignant Lymphoma
    View official trial listing →
  • Completed NCT NCT02689141

    Sequential Regimen of Bendamustin-Debulking Followed by Ofatumumab and Ibrutinib in CLL Patients (CLL2-BIO)

    Not yet reported German CLL Study Group 66 participants Est. completion 2020-02-06 1 site Stand-alone
    Other conditions: Chronic Lymphocytic Leukemia
    View official trial listing →
  • Completed NCT NCT02689986

    Bendamustine and Rituximab Combination Therapy for Cold Agglutinin Disease

    Not yet reported Helse Fonna 43 participants Est. completion 2016-12 8 sites Stand-alone
    Other conditions: Cold Agglutinin Disease, Autoimmune Hemolytic Anemia
    View official trial listing →
  • Active, not recruiting NCT NCT02717624

    A Study of Acalabrutinib in Combination With Rituximab + (Bendamustine or Venetoclax) in Subjects With MCL

    Not yet reported Acerta Pharma BV 72 participants Est. completion 2027-08-20 15 sites Stand-alone
    Other conditions: Mantle Cell Lymphoma (MCL)
    View official trial listing →
  • Completed NCT NCT02728531

    Bendamustine and Rituximab Alternating With Cytarabine and Rituximab for Untreated Mantle Cell Lymphoma

    Not yet reported Washington University School of Medicine 18 participants Est. completion 2023-08-16 1 site Stand-alone
    Other conditions: Mantle Cell Lymphoma
    View official trial listing →
  • Completed NCT NCT02733042

    A Study to Determine Dose, Safety, and Efficacy of Durvalumab as Monotherapy and in Combination Therapy in Subjects With Lymphoma or Chronic Lymphocytic Leukemia

    Not yet reported, Not yet reported Celgene 106 participants Est. completion 2022-08-21 66 sites Stand-alone
    Other conditions: Lymphoma, Leukemia, Lymphocytic, Chronic, B-Cell
    View official trial listing →
  • Status unknown NCT NCT02747732

    Study of Ibrutinib in Combination With Bendamustine and Rituximab for Patients With Relapsed/Refractory Aggressive BCL

    Not yet reported Meirav Kedmi MD 72 participants Est. completion 2021-10 2 sites Stand-alone
    Other conditions: Diffuse Large B Cell Lymphoma, Primary Mediastinal (Thymic) Large B-cell Lymphoma, Transformed Indolent Lymphoma, Recurrent Disease, Refractory Cancer
    View official trial listing →
  • Status unknown NCT NCT02753062

    Bendamustine Plus Subcutaneous Rituximab in Patients With Diffuse Large B-cell Lymphoma

    Not yet reported Asan Medical Center 22 participants Est. completion 2023-08 1 site Stand-alone
    Other conditions: Diffuse Large B Cell Lymphoma
    View official trial listing →
  • Status unknown NCT NCT02758925

    CyBeR Association in Relapsed/Refractory DLBCL

    Not yet reported University Hospital, Caen 78 participants Est. completion 2018-12 Stand-alone
    Other conditions: Diffuse Large B Cell Lymphoma
    View official trial listing →
  • Completed NCT NCT02763319

    A Trial to Evaluate the Efficacy and Safety of Tafasitamab With Bendamustine (BEN) Versus Rituximab (RTX) With BEN in Adult Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)

    Not yet reported, Not yet reported Incyte Corporation 453 participants Est. completion 2024-06-21 158 sites Stand-alone
    Other conditions: Diffuse Large B-cell Lymphoma
    View official trial listing →
  • Completed NCT NCT02788201

    Genomic Based Assignment of Therapy in Advanced Urothelial Carcinoma

    Not yet reported National Cancer Institute (NCI) 8 participants Est. completion 2019-10-23 1 site Stand-alone
    Other conditions: Urothelial Carcinoma, Bladder Cancer, Urinary Bladder Neoplasms
    View official trial listing →
  • Terminated NCT NCT02793583

    Study to Assess the Efficacy and Safety of Ublituximab + Umbralisib With or Without Bendamustine and Umbralisib Alone in Patients With Previously Treated Non-Hodgkins Lymphoma

    Not yet reported, Not yet reported TG Therapeutics, Inc. 710 participants Est. completion 2022-07-04 168 sites Stand-alone
    Other conditions: Diffuse Large B-Cell Lymphoma, Follicular Lymphoma, Marginal Zone Lymphoma, Mantle Cell Lymphoma, Small Lymphocytic Lymphoma
    View official trial listing →
  • Completed NCT NCT02799147

    GVHD Prophylaxis With Post-transplantation Bendamustine in Refractory Leukemia

    Not yet reported, Not yet reported St. Petersburg State Pavlov Medical University 27 participants Est. completion 2020-11 1 site Stand-alone
    Other conditions: Leukemia, Acute Lymphoblastic, Acute Myeloid Leukemia, Mixed-Lineage Acute Leukemias
    View official trial listing →
  • Status unknown NCT NCT02836639

    BEB Conditioning Regimen for Autologous Stem-cell Transplantation(ASCT) in Non-Hodgkin's Lymphoma

    Not yet reported Pusan National University Hospital 20 participants 1 site Stand-alone
    Other conditions: Lymphoma, Non-Hodgkin
    View official trial listing →
  • Completed NCT NCT02853370

    Bendamustine and Rituximab for the Treatment of Splenic Marginal Zone Lymphoma

    Not yet reported International Extranodal Lymphoma Study Group (IELSG) 78 participants Est. completion 2020-12 30 sites Stand-alone
    Other conditions: Marginal Zone B-cell Lymphoma
    View official trial listing →
  • Completed NCT NCT02927769

    A Study of Nivolumab Plus Brentuximab Vedotin in Patients Between 5 and 30 Years Old, With Hodgkin's Lymphoma (cHL), Relapsed or Refractory From First Line Treatment

    Not yet reported Bristol-Myers Squibb 72 participants Est. completion 2024-05-28 79 sites Stand-alone
    Other conditions: Hodgkin Disease
    View official trial listing →
  • Completed NCT NCT02950051

    Standard Chemoimmunotherapy (FCR/BR) Versus Rituximab + Venetoclax (RVe) Versus Obinutuzumab (GA101) + Venetoclax (GVe) Versus Obinutuzumab + Ibrutinib + Venetoclax (GIVe) in Fit Patients With Previously Untreated Chronic Lymphocytic Leukemia (CLL) Without Del(17p) or TP53 Mutation

    Not yet reported German CLL Study Group 926 participants Est. completion 2024-02-29 161 sites
    Other conditions: Chronic Lymphocytic Leukemia
    View official trial listing →
  • Terminated NCT NCT02951156

    Avelumab In Combination Regimens That Include An Immune Agonist, Epigenetic Modulator, CD20 Antagonist and/or Conventional Chemotherapy in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (R/R DLBCL)

    Not yet reported Pfizer 29 participants Est. completion 2019-12-02 29 sites Stand-alone
    Other conditions: Diffuse Large B-Cell Lymphoma
    View official trial listing →
  • Terminated NCT NCT02954406

    A Study of TAK-659 in Combination With Bendamustine (+/-Rituximab), Gemcitabine, Lenalidomide, or Ibrutinib for the Treatment of Participants With Advanced Non-Hodgkin Lymphoma

    Not yet reported Millennium Pharmaceuticals, Inc. 43 participants Est. completion 2020-07-27 13 sites Stand-alone
    Other conditions: Lymphoma, Non-Hodgkin
    View official trial listing →
  • Active, not recruiting NCT NCT02970318

    A Study of Acalabrutinib vs Investigator's Choice of Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in R/R CLL

    Not yet reported Acerta Pharma BV 310 participants Est. completion 2027-10-01 157 sites
    Other conditions: Chronic Lymphocytic Leukemia
    View official trial listing →
  • Active, not recruiting NCT NCT02972840

    A Study of BR Alone Versus in Combination With Acalabrutinib in Subjects With Previously Untreated MCL

    Not yet reported Acerta Pharma BV 635 participants Est. completion 2027-02-15 228 sites Stand-alone
    Other conditions: Lymphoma, Mantle Cell
    View official trial listing →
  • Completed NCT NCT02996773

    Haploidentical BMT With Post-Transplant Cyclophosphamide and Bendamustine

    Not yet reported University of Arizona 50 participants Est. completion 2025-08-01 1 site Stand-alone
    Other conditions: Acute Lymphoblastic Leukemia, Acute Myelogenous Leukemia, Myelodysplastic Syndromes, Chronic Myelogenous Leukemia, Lymphoma,Non-Hodgkin, Lymphoma, Hodgkin, Lymphoma, Follicular, Marginal Zone Lymphoma, Large Cell Lymphoma, Mantle-Cell Lymphoma, Gray Zone Lymphoma, Burkitt Lymphoma, High Risk Undifferentiated Acute Leukemia
    View official trial listing →
  • Completed NCT NCT03039114

    Study Evaluating Safety and Efficacy of INCB050465 Combined With Bendamustine and Obinutuzumab in Relapsed or Refractory Follicular Lymphoma (CITADEL-102)

    Not yet reported Incyte Corporation 26 participants Est. completion 2021-03-30 21 sites Stand-alone
    Other conditions: Lymphoma
    View official trial listing →
  • Completed NCT NCT03113422

    Phase II Venetoclax, Obinutuzumab and Bendamustine in High Tumor Burden Follicular Lymphoma as Front Line Therapy

    Not yet reported PrECOG, LLC. 56 participants Est. completion 2023-01-06 10 sites Stand-alone
    Other conditions: Follicular Lymphoma, Non-Hodgkin's Lymphoma Follicular, Non-Hodgkin's Lymphoma, Adult High Grade
    View official trial listing →
  • Suspended NCT NCT03187210

    Brentuximab Vedotin and BeEAM High-dose Chemotherapy in Lymphomas

    Not yet reported, Not yet reported Insel Gruppe AG, University Hospital Bern 20 participants Est. completion 2025-04-30 1 site Stand-alone
    Other conditions: Lymphoma
    View official trial listing →
  • Completed NCT NCT03187223

    Bendamustine and Melphalan in Myeloma

    Not yet reported Insel Gruppe AG, University Hospital Bern 120 participants Est. completion 2020-05-28 1 site Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Completed NCT NCT03259529

    Safety and Efficacy of Bendamustine, Gemcitabine, Rituximab, Nivolumab (BeGeRN) in Patients With r/r DLBCL

    Not yet reported, Not yet reported St. Petersburg State Pavlov Medical University 30 participants Est. completion 2020-01-27 1 site Stand-alone
    Other conditions: Diffuse Large B Cell Lymphoma
    View official trial listing →
  • Active, not recruiting NCT NCT03269669

    Obinutuzumab With or Without Umbralisib, Lenalidomide, or Combination Chemotherapy in Treating Patients With Relapsed or Refractory Grade I-IIIa Follicular Lymphoma

    Not yet reported National Cancer Institute (NCI) 73 participants Est. completion 2027-01-21 429 sites
    Other conditions: Grade 1 Follicular Lymphoma, Grade 2 Follicular Lymphoma, Grade 3a Follicular Lymphoma, Recurrent Follicular Lymphoma, Refractory Follicular Lymphoma
    View official trial listing →
  • Completed NCT NCT03295240

    The Study of Bendamustine, Rituximab, Ibrutinib, and Venetoclax in Relapsed, Refractory Mantle Cell Lymphoma

    Not yet reported Memorial Sloan Kettering Cancer Center 10 participants Est. completion 2024-01-22 7 sites Stand-alone
    Other conditions: Mantle Cell Lymphoma, Lymphoma
    View official trial listing →
  • Terminated NCT NCT03311126

    Bendamustine + Obinutuzumab Induction With Obinutuzumab Maintenance in Untreated Mantle Cell Lymphoma

    Not yet reported University of Wisconsin, Madison 21 participants Est. completion 2023-07-31 1 site Stand-alone
    Other conditions: Mantle Cell Lymphoma, Non-hodgkin Lymphoma, Non Hodgkin Lymphoma
    View official trial listing →
  • Status unknown NCT NCT03315520

    BeEAC Conditioning Regimen in Malignant Lymphoma Subjects With Indications to Autologous Hematopoietic Stem-cell Transplantation

    Not yet reported State Budgetary Healthcare Institution, National Medical Surgical Center N.A. N.I. Pirogov, Ministry of Health of Russia 100 participants Est. completion 2020-12-31 1 site Stand-alone
    Other conditions: Relapsed/Refractory Malignant Lymphomas
    View official trial listing →
  • Active, not recruiting NCT NCT03336333

    A Study Comparing Zanubrutinib With Bendamustine Plus Rituximab in Participants With Previously Untreated CLL or SLL

    Not yet reported BeiGene 590 participants Est. completion 2027-10-31 158 sites Stand-alone
    Other conditions: Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
    View official trial listing →
  • Completed NCT NCT03343652

    A Study of Safety and Efficacy of Nivolumab and Bendamustine (NB) in Patients With Relapsed/Refractory Hodgkin's Lymphoma

    Not yet reported, Not yet reported St. Petersburg State Pavlov Medical University 30 participants Est. completion 2020-03-27 1 site Stand-alone
    Other conditions: Hodgkin's Lymphoma
    View official trial listing →
  • Active, not recruiting NCT NCT03352765

    A Phase I Study of Bendamustine and Melphalan Conditioning and Autologous Stem Cell Transplantation for Treatment of Multiple Myeloma and Relapsed/Refractory B-cell Lymphoma in Elderly Patients

    Not yet reported Memorial Sloan Kettering Cancer Center 28 participants Est. completion 2026-11 1 site Stand-alone
    Other conditions: Lymphoma
    View official trial listing →
  • Status unknown NCT NCT03392714

    Bendamustine-based Combination Therapy for PCNSL

    Not yet reported Chonnam National University Hospital 15 participants Est. completion 2019-01-20 1 site Stand-alone
    Other conditions: PCNSL
    View official trial listing →
  • Completed NCT NCT03406156

    A Study in Previously Untreated Chronic Lymphocytic Leukemia (CLL) Subjects, Excluding Those With the 17p Deletion, to Evaluate Debulking Regimens Prior to Initiating Venetoclax Combination Therapy

    Not yet reported AbbVie 120 participants Est. completion 2023-07-12 15 sites Stand-alone
    Other conditions: Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL)
    View official trial listing →
  • Completed NCT NCT03424122

    INCB050465 in Combination With Rituximab, Bendamustine and Rituximab, or Ibrutinib in Participants With Previously Treated B-Cell Lymphoma (CITADEL-112)

    Not yet reported Incyte Corporation 50 participants Est. completion 2022-06-27 21 sites Stand-alone
    Other conditions: B-cell Lymphoma
    View official trial listing →
  • Completed NCT NCT03492775

    First Line Therapy of Advanced Stage Follicular Lymphoma in Patients < 60 Years Not Eligible fo Standard Immunochemotherapy and in All Patients ≥ 60 Years

    Not yet reported Prof. Dr. Wolfgang Hiddemann 46 participants Est. completion 2022-12-31 1 site
    Other conditions: Indolent Non-hodgkin Lymphoma
    View official trial listing →
  • Completed NCT NCT03524235

    Haploidentical Stem Cell Transplant with Prophylactic Natural Killer DLI for Lymphoma, Multiple Myeloma, and CLL

    Not yet reported Noah Merin 20 participants Est. completion 2024-11-06 1 site Stand-alone
    Other conditions: Multiple Myeloma, CLL, Chronic Lymphocytic Leukemia, Lymphoma, Hodgkin Lymphoma
    View official trial listing →
  • Completed NCT NCT03567876

    Rituximab, Bendamustine and Cytarabine Followed by Venetoclax in High Risk Elderly Patients With MCL

    Not yet reported Fondazione Italiana Linfomi - ETS 141 participants Est. completion 2025-10-15 35 sites
    Other conditions: Lymphoma, Mantle-Cell
    View official trial listing →
  • Completed NCT NCT03570892

    Tisagenlecleucel in Adult Patients With Aggressive B-cell Non-Hodgkin Lymphoma

    Not yet reported Novartis Pharmaceuticals 330 participants Est. completion 2026-02-03 67 sites Stand-alone
    Other conditions: Non-Hodgkin Lymphoma
    View official trial listing →
  • Completed NCT NCT03593018

    Efficacy and Safety of Oral Azacitidine Compared to Investigator's Choice Therapy in Patients With Relapsed or Refractory AITL

    Not yet reported The Lymphoma Academic Research Organisation 86 participants Est. completion 2025-08-28 27 sites
    Other conditions: Relapsed Angioimmunoblastic T-Cell Lymphoma, Refractory Angioimmunoblastic T-cell Lymphoma
    View official trial listing →
  • Active, not recruiting NCT NCT03602157

    Study of CAR-T Cells Expressing CD30 and CCR4 for r/r CD30+ HL and CTCL

    Not yet reported UNC Lineberger Comprehensive Cancer Center 43 participants Est. completion 2039-11-04 1 site Stand-alone
    Other conditions: Lymphoma, Immune System Diseases, Immunoproliferative Disorders, Lymphatic Diseases, Lymphoproliferative Disorders, Neoplasms, Cutaneous Lymphoma, Cutaneous Anaplastic Large Cell Lymphoma, Mycosis Fungoides, Sezary Syndrome, Lymphomatoid Papulosis, Cutaneous T Cell Lymphoma, Gray Zone Lymphoma
    View official trial listing →
  • Completed NCT NCT03604679

    SyB C-0501(Oral Bendamustine) in Patients With Advanced Solid Tumors

    Not yet reported SymBio Pharmaceuticals 18 participants Est. completion 2020-09-11 2 sites Stand-alone
    Other conditions: Advanced Solid Tumor
    View official trial listing →
  • Completed NCT NCT03609593

    Bendamustine/Rituximab Followed by Venetoclax and Rituximab for Treatment of Chronic Lymphocytic Leukemia

    Not yet reported Nicole Lamanna 42 participants Est. completion 2026-01-27 1 site Stand-alone
    Other conditions: Chronic Lymphocytic Leukemia
    View official trial listing →
  • Completed NCT NCT03615664

    The Efficacy of Salvage BGD With autoSCT Consolidation in Advanced Classical HL Patients Not Responding to ABVD

    Not yet reported Polish Lymphoma Research Group 115 participants Est. completion 2024-12-31 13 sites Stand-alone
    Other conditions: Hodgkin's Lymphoma
    View official trial listing →
  • Completed NCT NCT03623373

    Acalabrutinib With Bendamustine / Rituximab Followed by Cytarabine / Rituximab for Untreated Mantle Cell Lymphoma

    Not yet reported Washington University School of Medicine 13 participants Est. completion 2025-04-14 1 site Stand-alone
    Other conditions: Mantle Cell Lymphoma
    View official trial listing →
  • Active, not recruiting NCT NCT03696784

    Anti-CD19 CAR-T Cells With Inducible Caspase 9 Safety Switch for B-cell Lymphoma

    Not yet reported UNC Lineberger Comprehensive Cancer Center 12 participants Est. completion 2040-07-31 1 site Stand-alone
    Other conditions: Lymphoma, Lymphoma, B-Cell, Immune System Diseases, Immunoproliferative Disorders, Lymphatic Diseases
    View official trial listing →
  • Completed NCT NCT03739619

    Gemcitabine, Bendamustine, and Nivolumab in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma

    Not yet reported, Not yet reported Emory University 3 participants Est. completion 2025-04-30 2 sites Stand-alone
    Other conditions: Recurrent Hodgkin Lymphoma, Refractory Hodgkin Lymphoma, Classical Hodgkin Lymphoma, Hodgkin Lymphoma
    View official trial listing →
  • Active, not recruiting NCT NCT03755804

    Pediatric Classical Hodgkin Lymphoma Consortium Study: cHOD17

    Not yet reported St. Jude Children's Research Hospital 232 participants Est. completion 2028-07-01 8 sites Stand-alone
    Other conditions: Hodgkin Lymphoma
    View official trial listing →
  • Terminated NCT NCT03778073

    Study of Cosibelimab in Subjects With Relapsed or Refractory Lymphoma

    Not yet reported TG Therapeutics, Inc. 18 participants Est. completion 2022-08-01 9 sites Stand-alone
    Other conditions: B-cell Non Hodgkin Lymphoma, Richter's Transformation
    View official trial listing →
  • Completed NCT NCT03787264

    Sequential Regimen of Bendamustin-Debulking Followed by Obinutuzumab, Acalabrutinib and Venetoclax in Patients With Relapsed/Refractory CLL

    Not yet reported German CLL Study Group 46 participants Est. completion 2023-09-26 17 sites Stand-alone
    Other conditions: Chronic Lymphoid Leukemia
    View official trial listing →
  • Completed NCT NCT03817853

    An Open-Label, Single Arm Study of Obinutuzumab Short Duration Infusion in Patients With Previously Untreated Advanced Follicular Lymphoma

    Not yet reported Hoffmann-La Roche 114 participants Est. completion 2023-01-25 33 sites Stand-alone
    Other conditions: Advanced Follicular Lymphoma
    View official trial listing →
  • Status unknown NCT NCT03823365

    Blinatumomab Expanded T-cells (BET) in Indolent Non-Hodgkin Lymphomas/Chronic Lymphocytic Leukemia

    Not yet reported A.O. Ospedale Papa Giovanni XXIII 19 participants Est. completion 2022-11 1 site
    Other conditions: Indolent Non-Hodgkin Lymphomas/Chronic Lymphocytic Leukemia
    View official trial listing →
  • Completed NCT NCT03834688

    Phase II Study of Bendamustine and Rituximab Plus Venetoclax in Untreated Mantle Cell Lymphoma Over 60 Years of Age

    Not yet reported PrECOG, LLC. 33 participants Est. completion 2024-07-26 7 sites Stand-alone
    Other conditions: Mantle Cell Lymphoma
    View official trial listing →
  • Active, not recruiting NCT NCT03836261

    Study of Acalabrutinib (ACP-196) in Combination With Venetoclax (ABT-199), With and Without Obinutuzumab (GA101) Versus Chemoimmunotherapy for Previously Untreated CLL

    Not yet reported Acerta Pharma BV 984 participants Est. completion 2027-04-30 169 sites
    Other conditions: Chronic Lymphocytic Leukemia
    View official trial listing →
  • Status unknown NCT NCT03847727

    Bendamustine and Rituximab (BR) as Induction and Maintenance in Relapsed and Refractory Chronic Lymphocytic Leukemia

    Pirogov Russian National Research Medical University 112 participants Est. completion 2020-12-03 1 site
    Other conditions: Chronic Lymphocytic Leukemia
    View official trial listing →
  • Terminated NCT NCT03856216

    Inotuzumab Ozogamicin and Chemotherapy in Treating Patients With Leukemia or Lymphoma Undergoing Stem Cell Transplantation

    Not yet reported M.D. Anderson Cancer Center 15 participants Est. completion 2025-10-13 1 site Stand-alone
    Other conditions: Acute Lymphoblastic Leukemia, B Acute Lymphoblastic Leukemia, Lymphocytic Neoplasm, Lymphoma
    View official trial listing →
  • Active, not recruiting NCT NCT03872180

    Bendamustine, Obinutuzumab, and Venetoclax in Patients With Untreated Mantle Cell Lymphoma

    Not yet reported Emory University 23 participants Est. completion 2027-07-15 3 sites Stand-alone
    Other conditions: CCND1 Positive, Mantle Cell Lymphoma, t(11;14) Positive
    View official trial listing →
  • Status unknown NCT NCT03881592

    Real-World Data Study Focused on Chronic Lymphocytic Leukemia (CLL) Patient Treatment Options and Their Effectiveness

    Brno University Hospital 400 participants Est. completion 2019-09 2 sites
    Other conditions: Chronic Lymphocytic Leukemia
    View official trial listing →
  • Completed NCT NCT03900377

    Phase I/II Study of SyB L-0501RI in Combination With Rituximab to Treat Lymphoma

    Not yet reported, Not yet reported SymBio Pharmaceuticals 37 participants Est. completion 2021-02-26 14 sites
    Other conditions: Lymphoma, B-cell, Diffuse
    View official trial listing →
  • No Longer Available NCT NCT03914885

    Compassionate Use Re-Infusion of ATLCAR.CD30

    UNC Lineberger Comprehensive Cancer Center 1 site
    Other conditions: Hodgkin Lymphoma, Adult
    View official trial listing →
  • Completed NCT NCT03997968

    A Phase 1/2 Study of CYT-0851 in B-Cell Malignancies and Advanced Solid Tumors

    Not yet reported, Not yet reported Cyteir Therapeutics, Inc. 169 participants Est. completion 2024-12-20 16 sites Stand-alone
    Other conditions: Malignancy, Non-hodgkin Lymphoma, Multiple Myeloma, Breast Cancer, Ovarian Cancer, Soft Tissue Sarcoma, Head and Neck Cancer, DLBCL, Mantle Cell Lymphoma, Follicular Lymphoma, Pancreatic Cancer, CLL, Small Cell Lung Cancer, Squamous Cell Carcinoma of Head and Neck, Triple Negative Breast Cancer
    View official trial listing →
  • Active, not recruiting NCT NCT04002297

    A Study to Investigate the Efficacy of Zanubrutinib Plus Rituximab Compared With Bendamustine Plus Rituximab in Adults With Previously Untreated Mantle Cell Lymphoma Who Are Ineligible for Stem Cell Transplantation

    Not yet reported BeOne Medicines 510 participants Est. completion 2031-09-30 176 sites
    Other conditions: Mantle Cell Lymphoma; Non-Hodgkin Lymphoma
    View official trial listing →
  • Terminated NCT NCT04023071

    FT516 in Subjects With Advanced Hematologic Malignancies

    Not yet reported Fate Therapeutics 72 participants Est. completion 2023-10-23 7 sites Stand-alone
    Other conditions: Acute Myelogenous Leukemia, B-cell Lymphoma
    View official trial listing →
  • Completed NCT NCT04049825

    A Phase 1 Trial of OPB-111077 in Combination With Bendamustine and Rituximab in Patients With r/r DLBCL

    Not yet reported Otsuka Pharmaceutical Co., Ltd. 36 participants Est. completion 2026-01-19 1 site Stand-alone
    Other conditions: Relapsed or Refractory Diffuse Large B-cell Lymphoma
    View official trial listing →
  • Terminated NCT NCT04083898

    Isatuximab, Bendamustine, and Prednisone in Refractory Multiple Myeloma

    Not yet reported Washington University School of Medicine 15 participants Est. completion 2024-03-07 1 site Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Active, not recruiting NCT NCT04115631

    A Comparison of Three Chemotherapy Regimens for the Treatment of Patients With Newly Diagnosed Mantle Cell Lymphoma

    Not yet reported ECOG-ACRIN Cancer Research Group 360 participants Est. completion 2026-12-31 504 sites Stand-alone
    Other conditions: Liver Lymphoma, Mantle Cell Lymphoma
    View official trial listing →
  • Status unknown NCT NCT04127916

    Bendamustine Plus Rituximab for Mantle Cell Lymphoma: a Multicenter Retrospective Analysis(BR-MCL)

    Samsung Medical Center 40 participants Est. completion 2020-12-31 2 sites
    Other conditions: Mantle Cell Lymphoma
    View official trial listing →
  • Withdrawn NCT NCT04138875

    A Risk Stratified Sequential Treatment With Rituximab, Brentuximab Vedotin and Bendamustine (RBvB)

    Not yet reported Yale University Est. completion 2023-12 2 sites
    Other conditions: PTLD, Lymphoid Tumor, Hematopoietic/Lymphoid Cancer, Plasmacytic Hyperplasia PTLD, Infectious Mononucleosis, Florid Follicular Hyperplasia PTLD, Polymorphic PTLD, Monomorphic PTLD, Classical Hodgkin Lymphoma Type PTLD
    View official trial listing →
  • Terminated NCT NCT04155840

    Bendamustine and Rituximab in Combination With Copanlisib for the Treatment of Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

    Not yet reported University of Washington 1 participants Est. completion 2021-03-16 1 site Stand-alone
    Other conditions: Lymphoid Leukemia, Non-Hodgkin's Lymphoma, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
    View official trial listing →
  • Terminated NCT NCT04217317

    CPI-613 in Combination With Bendamustine in Patients With Relapsed/Refractory T-Cell Non-Hodgkin Lymphoma

    Not yet reported Wake Forest University Health Sciences 6 participants Est. completion 2024-07-11 1 site Stand-alone
    Other conditions: Relapsed T-Cell Lymphoma, Refractory T-Cell Lymphoma, Non Hodgkin Lymphoma
    View official trial listing →
  • Terminated NCT NCT04236141

    A Study to Evaluate the Efficacy and Safety of Polatuzumab Vedotin in Combination With Bendamustine and Rituximab Compared With Bendamustine and Rituximab Alone in Chinese Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (R/R DLBCL).

    Not yet reported Hoffmann-La Roche 42 participants Est. completion 2022-02-07 10 sites Stand-alone
    Other conditions: Diffuse, Large B-Cell, Lymphoma
    View official trial listing →
  • Terminated NCT NCT04245722

    FT596 as a Monotherapy and in Combination With Anti-CD20 Monoclonal Antibodies

    Not yet reported Fate Therapeutics 98 participants Est. completion 2023-09-27 9 sites Stand-alone
    Other conditions: Lymphoma, B-Cell, Chronic Lymphocytic Leukemia
    View official trial listing →
  • Active, not recruiting NCT NCT04268706

    Phase 2 Study Evaluating Autologous CD30.CAR-T Cells in Patients With Relapsed/Refractory Hodgkin Lymphoma (CHARIOT)

    Not yet reported Tessa Therapeutics 97 participants Est. completion 2037-03 5 sites Stand-alone
    Other conditions: Hodgkin Lymphoma, Adult, Hodgkin Disease Recurrent, Hodgkin Disease Refractory, Hodgkin Disease, Pediatric
    View official trial listing →
  • Completed NCT NCT04285567

    A Study to Compare the Efficacy and Safety of a Combined Regimen of Venetoclax and Obinutuzumab Versus Fludarabine, Cyclophosphamide, and Rituximab (FCR)/ Bendamustine And Rituximab (BR) in FIT Patients With Previously Untreated Chronic Lymphocytic Leukemia (CLL) Without DEL (17P) or TP53 Mutation

    Not yet reported Hoffmann-La Roche 166 participants Est. completion 2025-03-19 40 sites
    Other conditions: Chronic Lymphocytic Leukemia (CLL)
    View official trial listing →
  • Terminated NCT NCT04433182

    Copanlisib With Rituximab-Bendamustine in Patients With Relapsed-Refractory Diffuse Large B-cell Lymphoma

    Not yet reported Fondazione Italiana Linfomi - ETS 37 participants Est. completion 2024-12-19 17 sites Stand-alone
    Other conditions: Diffuse Large B-cell Lymphoma
    View official trial listing →
  • Active, not recruiting NCT NCT04515238

    Sequential Regimen of Bendamustine Followed by Obinutuzumab (GA101), Zanubrutinib (BGB-3111) and Venetoclax (ABT-199) in Patients With Relapsed/Refractory CLL

    Not yet reported German CLL Study Group 42 participants Est. completion 2027-02 11 sites Stand-alone
    Other conditions: Chronic Lymphoid Leukemia
    View official trial listing →
  • Active, not recruiting NCT NCT04526834

    Phase 1 Study of Autologous CD30.CAR-T in Relapsed or Refractory CD30 Positive Non-Hodgkin Lymphoma

    Not yet reported Tessa Therapeutics 21 participants Est. completion 2036-03 4 sites Stand-alone
    Other conditions: Anaplastic Large Cell Lymphoma, Peripheral T Cell Lymphoma, Extranodal NK/T-cell Lymphoma, Diffuse Large B Cell Lymphoma, Primary Mediastinal Large B-Cell Lymphoma (PMBCL)
    View official trial listing →
  • Withdrawn NCT NCT04535102

    POLA+BR for Relapsed or Refractory DLBCL

    Not yet reported University of Colorado, Denver Est. completion 2022-03-17
    Other conditions: Diffuse Large B Cell Lymphoma
    View official trial listing →
  • Completed NCT NCT04569838

    A Study to Evaluate the Efficacy and Safety of Bendamustine Hydrochloride Injection

    Not yet reported Chia Tai Tianqing Pharmaceutical Group Co., Ltd. 91 participants Est. completion 2016-08 11 sites Stand-alone
    Other conditions: Indolent B-Cell Non-Hodgkin's Lymphomas
    View official trial listing →
  • Withdrawn NCT NCT04607772

    Study of Selinexor in Combination With Backbone Treatments or Novel Therapies In Participants With Relapsed or Refractory (RR) Diffuse Large B-Cell Lymphoma (DLBCL)

    Not yet reported, Not yet reported Karyopharm Therapeutics Inc Est. completion 2025-12 18 sites Stand-alone
    Other conditions: Relapsed or Refractory Diffuse Large B-Cell Lymphoma
    View official trial listing →
  • Status unknown NCT NCT04624893

    A Multicenter, Retrospective Observational Study to Evaluate the Effectiveness and Safety of Polatuzumab Vedotin

    Jiangsu Cancer Institute & Hospital 35 participants Est. completion 2020-12 1 site
    Other conditions: Diffuse Large B-Cell Lymphoma (DLBCL)
    View official trial listing →
  • Active, not recruiting NCT NCT04624906

    Bendamustine, Rituximab and Acalabrutinib in Waldenstrom's Macroglobulinemia

    Not yet reported Sunnybrook Health Sciences Centre 63 participants Est. completion 2030-03 9 sites Stand-alone
    Other conditions: Waldenstrom Macroglobulinemia
    View official trial listing →
  • Active, not recruiting NCT NCT04629729

    FT819 in Subjects With B-cell Malignancies

    Not yet reported Fate Therapeutics 54 participants Est. completion 2039-09-30 18 sites Stand-alone
    Other conditions: Lymphoma, B-Cell, Chronic Lymphocytic Leukemia, Precursor B-Cell Acute Lymphoblastic Leukemia
    View official trial listing →
  • Active, not recruiting NCT NCT04663347

    Safety and Efficacy Trial of Epcoritamab Combinations in Subjects With B-cell Non-Hodgkin Lymphoma (B-NHL)

    Not yet reported, Not yet reported Genmab 543 participants Est. completion 2027-09-30 57 sites Stand-alone
    Other conditions: Diffuse Large B-Cell Lymphoma, Follicular Lymphoma
    View official trial listing →
  • Active, not recruiting NCT NCT04666038

    Study of LOXO-305 (Pirtobrutinib) Versus Investigator's Choice (Idelalisib Plus Rituximab or Bendamustine Plus Rituximab) in Patients With Previously Treated Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

    Not yet reported Loxo Oncology, Inc. 238 participants Est. completion 2027-05 232 sites
    Other conditions: Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
    View official trial listing →
  • Completed NCT NCT04673617

    AB-101 as Monotherapy and With Immunotherapy in Patients With Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma

    Not yet reported, Not yet reported Artiva Biotherapeutics, Inc. 45 participants Est. completion 2025-10-06 21 sites Stand-alone
    Other conditions: Non Hodgkin Lymphoma
    View official trial listing →
  • Completed NCT NCT04674813

    A Study of CC-95266 in Participants With Relapsed and/or Refractory Multiple Myeloma

    Not yet reported Juno Therapeutics, a Subsidiary of Celgene 130 participants Est. completion 2025-12-22 10 sites Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Terminated NCT NCT04727151

    TAC T-cells for the Treatment of HER2-positive Solid Tumors

    Not yet reported, Not yet reported Triumvira Immunologics, Inc. 28 participants Est. completion 2024-03-25 11 sites Stand-alone
    Other conditions: HER2 Positive Gastric Cancer, Metastatic HER2 Positive Gastroesophageal Junction Cancer
    View official trial listing →
  • Terminated NCT NCT04745832

    Phase 3 Study of Zandelisib (ME-401) in Combination With Rituximab in Patients With iNHL - (COASTAL)

    Not yet reported MEI Pharma, Inc. 82 participants Est. completion 2023-03-20 141 sites Stand-alone
    Other conditions: Follicular Lymphoma (FL), Non Hodgkin Lymphoma, Marginal Zone Lymphoma
    View official trial listing →
  • Status unknown NCT NCT04762745

    The Efficacy and Safety of Pomalidomide and Bendamustine With Dexamethasone in Relapsed or Refractory Multiple Myeloma

    Not yet reported, Not yet reported Sun Yat-sen University 56 participants Est. completion 2023-02 1 site Stand-alone
    Other conditions: Relapsed, Refractory, Multiple Myeloma
    View official trial listing →
  • Terminated NCT NCT04809766

    Mesothelin-Specific T-Cells (FH-TCR-Tᴍsʟɴ) for the Treatment of Metastatic Pancreatic Ductal Adenocarcinoma

    Not yet reported Fred Hutchinson Cancer Center 9 participants Est. completion 2025-01-15 1 site Stand-alone
    Other conditions: Metastatic Pancreatic Ductal Adenocarcinoma, Stage IV Pancreatic Cancer AJCC v8
    View official trial listing →
  • Status unknown NCT NCT04842318

    Rituximab Maintenance Treatment of Newly Diagnosed Follicular Lymphoma After BR or RCHOP or R2: a Multicenter Clinical Study

    Not yet reported Ruijin Hospital 789 participants Est. completion 2024-03-01 1 site Stand-alone
    Other conditions: Follicular Lymphoma
    View official trial listing →
  • Withdrawn NCT NCT04849715

    A Study of Parsaclisib, a PI3Kδ Inhibitor, in Combination With Bendamustine and Rituximab in Patients With Newly Diagnosed Mantle Cell Lymphoma

    Not yet reported Incyte Corporation Est. completion 2034-07-07
    Other conditions: Mantle Cell Lymphoma
    View official trial listing →
  • Withdrawn NCT NCT04882163

    Study to Evaluate Tolerability of Iberdomide (CC-220) in Combination With Polatuzumab Vedotin Plus Rituximab or Tafasitamab or Rituximab Plus Chemotherapy in B-cell Lymphoma

    Not yet reported, Not yet reported Celgene Est. completion 2029-04-07 27 sites Stand-alone
    Other conditions: Lymphoma, B-Cell
    View official trial listing →
  • Status unknown NCT NCT04897477

    Azacytidine, Bendamustine, Piamprizumab in Refractory/Relapsed B-cell Non-Hodgkin's Lymphoma

    Not yet reported, Not yet reported Chinese PLA General Hospital 30 participants Est. completion 2023-04-23 2 sites Stand-alone
    Other conditions: Non-hodgkin Lymphoma,B Cell
    View official trial listing →
  • Not yet recruiting NCT NCT04913103

    Study of PV in Combination With Bendamustine and Rituximab for Patients With R/R MCL

    Not yet reported Czech Lymphoma Study Group 21 participants Est. completion 2027-08-31 7 sites Stand-alone
    Other conditions: Lymphoma, Mantle-Cell
    View official trial listing →
  • Status unknown NCT NCT04934930

    Adjustment of Chemotherapy Duration in Follicular Lymphoma According to Minimal Residual Disease Status

    Not yet reported Meir Medical Center 40 participants Est. completion 2025-08-01 1 site Stand-alone
    Other conditions: Follicular Lymphoma
    View official trial listing →
  • Completed NCT NCT04942730

    Benadamustine, Fludarabine and Busulfan Conditioning in Recipients of Haploidentical Stem Cell Transplantation (FluBuBe)

    Not yet reported St. Petersburg State Pavlov Medical University 50 participants Est. completion 2024-04-30 1 site Stand-alone
    Other conditions: Leukemia, Acute Lymphoblastic, Myeloid Leukemia, Acute, Biphenotypic Acute Leukemia, Lymphoblastic Lymphoma, Myelodysplastic Syndromes, Myeloproliferative Neoplasm
    View official trial listing →
  • Withdrawn NCT NCT04943302

    Isatuximab and Bendamustine in Systemic Light Chain Amyloidosis

    Not yet reported Tufts Medical Center Est. completion 2026-01 Stand-alone
    Other conditions: Amyloidosis, Light Chain (AL) Amyloidosis
    View official trial listing →
  • Completed NCT NCT04943757

    Post-transplantation Benadamustine and Cyclophosphamide in Patients With Refractory Myeloid Malignancies

    Not yet reported St. Petersburg State Pavlov Medical University 50 participants Est. completion 2024-05-30 1 site Stand-alone
    Other conditions: Myeloid Leukemia, Acute, Chronic Myeloid Leukemia, Myelodysplastic Syndromes, Myeloproliferative Neoplasm
    View official trial listing →
  • Status unknown NCT NCT05006469

    Observation of the Efficacy of BAd Regimen in the Treatment of Relapsed and Refractory Multiple Myeloma

    Not yet reported Liao Aijun 10 participants Est. completion 2024-05-31 1 site Stand-alone
    Other conditions: Bendamustine, Multiple Myeloma
    View official trial listing →
  • Completed NCT NCT05007860

    Vaccine Responsiveness in Patients With Chronic Lymphocytic Leukemia

    Massachusetts General Hospital 36 participants Est. completion 2023-06-30 1 site
    Other conditions: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
    View official trial listing →
  • Active, not recruiting NCT NCT05023980

    A Study of Pirtobrutinib (LOXO-305) Versus Bendamustine Plus Rituximab (BR) in Untreated Patients With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

    Not yet reported Loxo Oncology, Inc. 282 participants Est. completion 2027-10 108 sites
    Other conditions: Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
    View official trial listing →
  • Terminated NCT NCT05025423

    Phase II Trial of Venetoclax and Rituximab as Initial Therapy in Older Patients With Mantle Cell Lymphoma

    Not yet reported Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins 7 participants Est. completion 2025-05-14 1 site Stand-alone
    Other conditions: Mantle Cell Lymphoma
    View official trial listing →
  • Active, not recruiting NCT NCT05058404

    Shortened vs Standard Chemotherapy Combined With Immunotherapy for the Initial Treatment of Patients With High Tumor Burden Follicular Lymphoma

    Not yet reported Fondazione Italiana Linfomi - ETS 605 participants Est. completion 2030-07 54 sites Stand-alone
    Other conditions: Follicular Lymphoma
    View official trial listing →
  • Completed NCT NCT05182073

    FT576 in Subjects With Multiple Myeloma

    Not yet reported Fate Therapeutics 31 participants Est. completion 2024-10-18 14 sites Stand-alone
    Other conditions: Multiple Myeloma, Myeloma
    View official trial listing →
  • Active, not recruiting NCT NCT05249959

    Consolidation With Loncastuximab Tesirine After a Short Course of Immunochemotherapy in BTKi-treated (or Intolerant) Relapsed/Refractory Mantle Cell Lymphoma Patients.

    Not yet reported Fondazione Italiana Linfomi - ETS 49 participants Est. completion 2029-03 19 sites Stand-alone
    Other conditions: Relapsed Mantle Cell Lymphoma, Refractory Mantle Cell Lymphoma
    View official trial listing →
  • Status unknown NCT NCT05287984

    Zanubrutinib Followed Zanubrutinib Plus FCR / BR in Newly Diagnosed Symptomatic CLL/SLL

    Not yet reported Institute of Hematology & Blood Diseases Hospital, China 63 participants Est. completion 2024-11-29 1 site Stand-alone
    Other conditions: Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Newly Diagnosed
    View official trial listing →
  • Active, not recruiting NCT NCT05300282

    Study of Atezolizumab Plus BEGEV Regimen in Relapsed or Refractory Hodgkin's Lymphoma Patients

    Not yet reported, Not yet reported Fondazione Italiana Linfomi - ETS 122 participants Est. completion 2029-12-15 28 sites
    Other conditions: Relapsed or Refractory Hodgkin's Lymphoma
    View official trial listing →
  • Active, not recruiting NCT NCT05352828

    Autologous CD30.CAR-T in Combination With Nivolumab in cHL Patients After Failure of Frontline Therapy

    Not yet reported Tessa Therapeutics 15 participants Est. completion 2037-12-15 5 sites Stand-alone
    Other conditions: Classical Hodgkin Lymphoma, Hodgkin Disease Refractory, Hodgkin Disease Recurrent
    View official trial listing →
  • Active, not recruiting NCT NCT05371093

    Study of Axicabtagene Ciloleucel Versus Standard of Care Therapy in Participants With Relapsed/Refractory Follicular Lymphoma

    Not yet reported Kite, A Gilead Company 231 participants Est. completion 2030-10 52 sites
    Other conditions: Relapsed/Refractory Follicular Lymphoma
    View official trial listing →
  • Status unknown NCT NCT05406154

    Ibrutinib Combined With Bendamustine and Rituximab in Newly Diagnosed Mantle Cell Lymphoma Patients Who Aged > 65 Years

    Peking University Third Hospital 60 participants Est. completion 2024-07-30 1 site
    Other conditions: Mantle Cell Lymphoma (MCL)
    View official trial listing →
  • Active, not recruiting NCT NCT05451771

    Venetoclax-Dexamethasone in Relapsed and/or Refractory t(11;14) Amyloidosis

    Not yet reported, Not yet reported Columbia University 53 participants Est. completion 2027-09 4 sites
    Other conditions: AL Amyloidosis
    View official trial listing →
  • Completed NCT NCT05508867

    A Study of Coformulated Favezelimab/Pembrolizumab (MK-4280A) Versus Physician's Choice Chemotherapy in PD-(L)1-refractory, Relapsed or Refractory Classical Hodgkin Lymphoma (MK-4280A-008)

    Not yet reported Merck Sharp & Dohme LLC 203 participants Est. completion 2026-01-08 105 sites
    Other conditions: Hodgkin Lymphoma
    View official trial listing →
  • Active, not recruiting NCT NCT05551936

    A Study of Tazemetostat With Rituximab and Abbreviated Bendamustine in the Frontline Treatment of High Tumor Burden Follicular Lymphoma

    Not yet reported, Not yet reported Vaishalee Kenkre 42 participants Est. completion 2027-05 5 sites Stand-alone
    Other conditions: Follicular Lymphoma
    View official trial listing →
  • Active, not recruiting NCT NCT05624554

    A Study of Nemtabrutinib vs Chemoimmunotherapy for Participants With Previously Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Without TP53 Aberrations (MK-1026-008, BELLWAVE-008)

    Not yet reported Merck Sharp & Dohme LLC 300 participants Est. completion 2031-03-17 97 sites
    Other conditions: Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
    View official trial listing →
  • Status unknown NCT NCT05660993

    Multicenter Study of Safety and Efficacy of PET-adapted Treatment With Nivolumab, Bendamustine, Gemcitabine, Vinorelbine (Nivo-BeGEV) in Patients With Relapsed/Refractory Hodgkin Lymphoma

    Not yet reported National Research Center for Hematology, Russia 50 participants Est. completion 2025-03-01 1 site Stand-alone
    Other conditions: Hodgkin Lymphoma
    View official trial listing →
  • Withdrawn NCT NCT05711628

    A Trial Comparing Chemotherapy Versus Novel Immune Checkpoint Inhibitor (Pembrolizumab) Plus Chemotherapy in Treating Relapsed/Refractory Classical Hodgkin Lymphoma

    Not yet reported National Cancer Institute (NCI) Est. completion 2028-06-30 Stand-alone
    Other conditions: Recurrent Classic Hodgkin Lymphoma, Refractory Classic Hodgkin Lymphoma
    View official trial listing →
  • Status unknown NCT NCT05757466

    Prolgolimab Monotherapy or in Combination With Bendamustine for r/r Classical Hodgkin Lymphoma

    Not yet reported St. Petersburg State Pavlov Medical University 30 participants Est. completion 2025-03-10 2 sites Stand-alone
    Other conditions: Hodgkin Lymphoma
    View official trial listing →
  • Completed NCT NCT05813132

    BeEAM Versus CEM in Lymphoma Patients as a Conditioning Regimen Before Autologous Hematopoietic Cell Transplantation

    Not yet reported Rehab Werida 58 participants Est. completion 2023-12-30 1 site
    Other conditions: Lymphoma
    View official trial listing →
  • Active, not recruiting NCT NCT05888493

    A Phase III Trial Comparing Tisagenlecleucel to Standard of Care (SoC) in Adult Participants With r/r Follicular Lymphoma

    Not yet reported Novartis Pharmaceuticals 109 participants Est. completion 2031-02-20 30 sites Stand-alone
    Other conditions: Follicular Lymphoma (FL)
    View official trial listing →
  • Status unknown NCT NCT05914662

    Zanubrutinib Plus BR in Newly Diagnosed Symptomatic WM

    Not yet reported Institute of Hematology & Blood Diseases Hospital, China 42 participants Est. completion 2025-12-15 1 site Stand-alone
    Other conditions: Waldenstrom Macroglobulinemia
    View official trial listing →
  • Not yet recruiting NCT NCT05918276

    Clinical Study of Orelabrutinib Combined With BG Regimen First-line Treatment of CLL/SLL

    Not yet reported Nanfang Hospital, Southern Medical University 24 participants Est. completion 2026-12-30 2 sites
    Other conditions: CLL/SLL
    View official trial listing →
  • Withdrawn NCT NCT05934097

    FT596 in Combination With R-CHOP in Subjects With B-Cell Lymphoma

    Not yet reported Fate Therapeutics Est. completion 2039-05 Stand-alone
    Other conditions: Diffuse Large B Cell Lymphoma, Transformed Indolent Non-Hodgkin's Lymphoma, Follicular Lymphoma, Mantle Cell Lymphoma, Marginal Zone Lymphoma
    View official trial listing →
  • Completed NCT NCT05950334

    FT522 With Rituximab in Relapsed/Refractory B-Cell Lymphoma (FT522-101)

    Not yet reported Fate Therapeutics 20 participants Est. completion 2025-06-30 7 sites Stand-alone
    Other conditions: Relapsed/Refractory B-Cell Lymphoma
    View official trial listing →
  • Status unknown NCT NCT05979948

    A Phase 2 Clinical Trial to Evaluate Zanubrutinib Combined With BR (Bendamustine/Rituximab) Regimen in Subjects With Newly-diagnosed Waldenström's Macroglobulinemia

    Not yet reported Shanghai Changzheng Hospital 60 participants Est. completion 2025-12-01 1 site Stand-alone
    Other conditions: Waldenström's Macroglobulinemia
    View official trial listing →
  • Withdrawn NCT NCT06094842

    Autologous T Cells Lentivirally Transduced to Express L1CAM-Specific Chimeric Antigen Receptors in Treating Patients With Locally Advanced and Unresectable or Metastatic Small Cell Neuroendocrine Prostate Cancer

    Not yet reported Fred Hutchinson Cancer Center Est. completion 2028-03-15 1 site Stand-alone
    Other conditions: Prostate Carcinoma, Prostate Small Cell Neuroendocrine Carcinoma, Stage III Prostate Cancer AJCC v8, Stage IV Prostate Cancer AJCC v8
    View official trial listing →
  • Active, not recruiting NCT NCT06191744

    Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Previously Untreated Follicular Lymphoma

    Not yet reported Genmab 1095 participants Est. completion 2037-11 266 sites Stand-alone
    Other conditions: Follicular Lymphoma (FL)
    View official trial listing →
  • Withdrawn NCT NCT06205290

    A Study to Compare the Efficacy and Safety of Lisocabtagene Maraleucel vs Investigator's Choice Options in Adult Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma, Whose Disease Has Failed Treatment With Both BTKi and BCL2i Therapies

    Not yet reported Juno Therapeutics, Inc., a Bristol-Myers Squibb Company Est. completion 2031-10-13 48 sites
    Other conditions: Leukemia, Lymphocytic, Chronic, B-Cell
    View official trial listing →
  • Active, not recruiting NCT NCT06284122

    Study of Mosunetuzumab Plus Lenalidomide Compared to Anti-CD20 Anti-body + Chemotherapy in Follicular Lymphoma FLIPI2-5

    Not yet reported The Lymphoma Academic Research Organisation 790 participants Est. completion 2034-04 111 sites
    Other conditions: Follicular Lymphoma
    View official trial listing →
  • Completed NCT NCT06295211

    Brentuximab Vedotin Combined With Bendamustine Supercharge, a Low-toxicity and Efficient Salvage Regimen for Primary Refractory or First-relapsed Classic Hodgkin Lymphoma: Long-term Results of a Retrospective Monocenter Study.

    Federico II University 32 participants Est. completion 2024-02-22
    Other conditions: Hodgkin Lymphoma
    View official trial listing →
  • Withdrawn NCT NCT06313996

    A Study to Evaluate the Efficacy and Safety of Liso-cel Compared to Standard of Care in Adults With Relapsed or Refractory Follicular Lymphoma

    Not yet reported Juno Therapeutics, Inc., a Bristol-Myers Squibb Company Est. completion 2031-10-16
    Other conditions: Relapsed or Refractory Follicular Lymphoma
    View official trial listing →
  • Status unknown NCT NCT06415708

    Obinutuzumab Combined With Bendamustine in the Treatment of Mature B-cell Lymphoma

    Not yet reported Institute of Hematology & Blood Diseases Hospital, China 134 participants Est. completion 2026-06-30 1 site Stand-alone
    Other conditions: B Cell Lymphoma
    View official trial listing →
  • Active, not recruiting NCT NCT06425302

    A Study to Evaluate the Efficacy and Safety of Golcadomide in Combination With Rituximab in Participants With Newly Diagnosed Advanced Stage Follicular Lymphoma

    Not yet reported Celgene 95 participants Est. completion 2028-11-27 56 sites Stand-alone
    Other conditions: Lymphoma, Follicular
    View official trial listing →
  • Not yet recruiting NCT NCT06465446

    A Study of IMM01 Plus Tiselizumab Versus Physician's Choice Chemotherapy in PD(L)1-refractory Classical Hodgkin Lymphoma

    Not yet reported ImmuneOnco Biopharmaceuticals (Shanghai) Inc. 202 participants Est. completion 2029-07
    Other conditions: Classic Hodgkin Lymphoma
    View official trial listing →
  • Not yet recruiting NCT NCT06557330

    MRD Guided De-intensification of Bendamustine/Rituximab for Indolent Non-Hodgkin Lymphoma

    Not yet reported Fox Chase Cancer Center 24 participants Est. completion 2028-03-30 Stand-alone
    Other conditions: Lymphoma, Indolent Non-hodgkin Lymphoma
    View official trial listing →
  • Not yet recruiting NCT NCT06563778

    Chidamide+Decitabine Plus Anti-PD-1 Antibody for Patients With R/R cHL Who Are Transplant-ineligible or Refused Transplant.

    Not yet reported Chinese PLA General Hospital 100 participants Est. completion 2028-09-01 1 site
    Other conditions: Ineligible Or Refused Transplant Patients With Classical Hodgkin Lymphoma
    View official trial listing →
  • Active, not recruiting NCT NCT06734078

    An Italian Multicenter Retrospective Observational Study to Assess the Clinical Characteristics and the Outcome of Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma Treated With Polatuzumab Vedotin Plus Rituximab (± Bendamustine) Under Named Patient Programme

    IRCCS Azienda Ospedaliero-Universitaria di Bologna 100 participants Est. completion 2025-12-31 9 sites
    Other conditions: DLBCL - Diffuse Large B Cell Lymphoma
    View official trial listing →
  • Not yet recruiting NCT NCT06741813

    Allo-HSCT vs ASCT in Adult T-LBL

    Not yet reported Peking University People's Hospital 230 participants Est. completion 2029-12-31
    Other conditions: T Lymphoblastic Lymphoma
    View official trial listing →
  • Not yet recruiting NCT NCT06757478

    A Clinical Study on the Combination of Mitoxantrone Liposome Injection, Bendamustine, Etoposide, and Cytarabine for Pretreatment of Autologous Hematopoietic Stem Cell Transplantation in Patients with Lymphoma

    First Affiliated Hospital of Ningbo University 30 participants Est. completion 2027-06-30
    Other conditions: Lymphoma Patient
    View official trial listing →
  • Not yet recruiting NCT NCT06757894

    Efficacy and Safety of Zuberitamab Combined with Bendamustine, Followed by Monotherapy Maintenance, in Treatment-naïve Follicular Lymphoma

    Not yet reported Sun Yat-sen University 50 participants Est. completion 2034-02-01 1 site Stand-alone
    Other conditions: Follicular Lymphoma (FL)
    View official trial listing →
  • Not yet recruiting NCT NCT06761911

    BV in the Treatment of Relapsed/refractory Hodgkin Lymphoma

    Not yet reported Xiuhua Sun 100 participants Est. completion 2026-01-31
    Other conditions: Hodgkin Lymphoma (Category)
    View official trial listing →
  • Enrolling by invitation NCT NCT06931613

    Autologous Hematopoietic Stem Cell Transplantation in Pediatric Relapsed or Refractory Hodgkin Lymphoma After Nivolumab Treatment

    Not yet reported St. Petersburg State Pavlov Medical University 20 participants Est. completion 2027-06-01 2 sites Stand-alone
    Other conditions: Relapsed or Refractory Hodgkin Lymphoma, Children, Nivolumab, Autologous Haemopoietic Stem Cell Transplant
    View official trial listing →
  • Not yet recruiting NCT NCT06942507

    Zanubrutinib Combined With BR in the First-line Treatment of Waldenström's Macroglobulinemia

    Not yet reported Peking Union Medical College Hospital 104 participants Est. completion 2029-04-30 1 site Stand-alone
    Other conditions: Waldenström's Macroglobulinemia (WM)
    View official trial listing →
  • Not yet recruiting NCT NCT06961500

    Obinutuzumab With CHOP Versus Obinutuzumab With Bendamustine in the Treatment of Newly Diagnosed Follicular Lymphoma Grade 3A

    Not yet reported Sun Yat-sen University 133 participants Est. completion 2030-11-01 1 site Stand-alone
    Other conditions: Follicular Lymphoma Grade 3A
    View official trial listing →
  • Active, not recruiting NCT NCT06970743

    A Study of BGB-16673 Compared to Investigator's Choice in Participants With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Covalent Bruton Tyrosine Kinase (BTK) Inhibitors

    Not yet reported BeOne Medicines 153 participants Est. completion 2029-11-30 56 sites
    Other conditions: Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
    View official trial listing →
  • Not yet recruiting NCT NCT07003464

    Phase II Trial of Zanubrutinib, Obinutuzumab, Bendamustine (ZGB) as First-Line Therapy for Chronic Lymphocytic Leukemia: A Single-Center Study

    Not yet reported The First Hospital of Jilin University 30 participants Est. completion 2028-06-01 1 site Stand-alone
    Other conditions: Chronic Lymphocytic Leukemia
    View official trial listing →
  • Not yet recruiting NCT NCT07008053

    BR Combined With OR in Treatment-naïve Marginal Zone Lymphoma

    Not yet reported Tianjin Medical University Cancer Institute and Hospital 37 participants Est. completion 2028-11 6 sites Stand-alone
    Other conditions: Marginal Zone Lymphomas
    View official trial listing →
  • Completed NCT NCT07145125

    Real-life Efficacy and Toxicity of Brentuximab-Vedotin Associated With Bendamustine in Patients With Relapsed or Refractory Hodgkin Lymphoma (HL-R2-B2)

    University Hospital, Bordeaux 222 participants Est. completion 2025-09-30 5 sites
    Other conditions: Relapsed or Refractory Hodgkin Lymphoma
    View official trial listing →
  • Not yet recruiting NCT NCT07166549

    Bispecific CAR T Cells for B-cell Malignancies (BaseCAR-01 Trial)

    Not yet reported University Hospital, Basel, Switzerland 12 participants Est. completion 2028-11 1 site Stand-alone
    Other conditions: B Cell Malignancies, B-cell Leukemia, B Cell Lymphoma, Bispecific Chimeric Antigen Receptor (CAR) T Cells, Relapsed or Refractory (r/r) B-cell Malignancies
    View official trial listing →
  • Not yet recruiting NCT NCT07169565

    Ibrutinib Followed by BR (Bendamustine and Rituximab) as a Time-Limited Therapy for Waldenström Macroglobulinemia

    Not yet reported Institute of Hematology & Blood Diseases Hospital, China 21 participants Est. completion 2028-09-01 Stand-alone
    Other conditions: Waldenström Macroglobulinemia (WM)
    View official trial listing →
  • Not yet recruiting NCT NCT07206264

    Chemotherapy Combined With Targeted Therapy as First-line Treatment for Mantle Cell Lymphoma Based on MRD and PET-CT Assessment

    Not yet reported Tianjin Medical University Cancer Institute and Hospital 45 participants Est. completion 2028-12 5 sites Stand-alone
    Other conditions: Mantle Cell Lymphoma
    View official trial listing →
  • Not yet recruiting NCT NCT07259122

    A Phase II Clinical Study of Zanubrutinib Combined With Four Cycles of CD20 Monoclonal Antibody and Reduced-Dose Bendamustine in the Treatment of Untreated Waldenström Macroglobulinemia

    Not yet reported Institute of Hematology & Blood Diseases Hospital, China 43 participants Est. completion 2032-06-30 2 sites Stand-alone
    Other conditions: Waldenström Macroglobulinemia (WM)
    View official trial listing →
  • Completed NCT NCT07450508

    Study of Bendamustine, Gemcitabine and Vinorelbine Regimen in Relapsed/Refractory Classical Hodgkin Lymphoma

    Not yet reported Cairo University 88 participants Est. completion 2026-02-01 1 site
    Other conditions: Classical Hodgkin Lymphoma Relapsed
    View official trial listing →
  • Not yet recruiting NCT NCT07492407

    CD20 Monoclonal Antibody-Based First-Line Therapy in Treatment-Naive Marginal Zone B-Cell Lymphoma

    Henan Cancer Hospital 131 participants Est. completion 2028-02
    Other conditions: MZL
    View official trial listing →
  • Not yet recruiting NCT NCT07575893

    CD30 CAR-T Cells for Low Risk Relapsed Classical Hodgkin Lymphoma

    Not yet reported New York Medical College 12 participants Est. completion 2032-12-01 Stand-alone
    Other conditions: Classical Hodgkin Lymphoma
    View official trial listing →
  • Not yet recruiting NCT NCT07593482

    Bendamustine Versus Fludarabine/Cyclophosphamide for Lymphodepletion in Chimeric Antigen Receptor T-cell Immunotherapy (CAR-T): a Randomized Trial.

    Not yet reported Swiss Cancer Institute 92 participants Est. completion 2030-03 9 sites Stand-alone
    Other conditions: B-cell Lymphoma
    View official trial listing →
  • Not yet recruiting NCT NCT07719855

    A Multicenter, Prospective, Open-Label, Randomized Controlled Clinical Study of Orelabrutinib Combined With Obinutuzumab and Lenalidomide Versus Obinutuzumab Plus Chemotherapy for Treatment-Naive Follicular Lymphoma

    Not yet reported Ruijin Hospital 652 participants Est. completion 2033-12 1 site
    Other conditions: Follicular Lymphoma ( FL)
    View official trial listing →
  • Not yet recruiting NCT NCT07725406

    Low-Dose TBI Plus CAR T-Cell Therapy for Relapsed/Refractory DLBCL and Multiple Myeloma

    Not yet reported Weill Medical College of Cornell University 32 participants Est. completion 2033-08-31 1 site Stand-alone
    Other conditions: Relapsed or Refractory Diffuse Large B Cell Lymphoma (DLBCL), Relapsed or Refractory Multiple Myeloma (MM)
    View official trial listing →
  • Not yet recruiting NCT NCT07753369

    A Clinical Trial to Evaluate the Efficacy and Safety of TQB3909 Tablets Versus Investigator's Choice in the Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)

    Not yet reported Chia Tai Tianqing Pharmaceutical Group Co., Ltd. 128 participants Est. completion 2030-12 2 sites
    Other conditions: Small Lymphocytic Lymppho, Relapsed/Refractory Chronic Lymphocytic Leukemia
    View official trial listing →
  • Not yet recruiting NCT NCT07790575

    Autoimmune Cytopenia Elimination by Chimeric Antigen Receptor T-cell Therapy

    Not yet reported Saurabh Dahiya 16 participants Est. completion 2041-07 1 site Stand-alone
    Other conditions: Cytopenia
    View official trial listing →
Efficacy history

Not yet reported.

Safety

Not yet reported.

Sources

Also known as: Bendamustine Hydrochloride, Bendamustine, Treanda

Related On The Pen coverage

No related coverage yet.

This drug may be investigational and not yet approved for any use. Whether someone can join a clinical trial is determined only by that trial's own study team — On The Pen does not determine eligibility. Information here can change; always confirm current details on the official ClinicalTrials.gov listing or with the sponsor.